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EXECUTIVE SUMMARY 
Yersinia ruckeri, a Gram-negative bacteria, is a pathogen which causes yersiniosis and 
significant losses in farmed Atlantic salmon (Salmo salar) in the Southern Hemisphere. 
Currently, Yersinivac-B, prepared from formalin killed whole-cells, is a commercial 
bacterin-based vaccine manufactured by MSD Animal Health. It is delivered by bath 
immersion vaccination against Y. ruckeri for most Tasmanian Atlantic salmon. Signifi-
cant mortality events may still occur despite vaccination. 
This thesis focused on the improvement of yersiniosis vaccine efficacy for Atlantic 
salmon by using different administrated methods of immersion immunisation. The 
following aims were addressed in this thesis: 
 Evaluate the effects of different inactivation methods of Y. ruckeri on the effica-
cy of single dip vaccines including formalin inactivation, ammonium sulphate
inactivation, and pH-lysed then formalin treated inactivation.
 Compare hyperosmotic pretreatment with direct immersion in Atlantic salmon
(Salmo salar) by using an ammonium sulphate inactivated Y. ruckeri whole-cell
vaccine.
 Investigate the vaccine performance of immersion vaccination with single dip
and double dip vaccination of small fish at hatchery stage.
In this thesis, three different experiments were carried out to obtain the results. The first 
experiment where the vaccine efficacy of Atlantic salmon was determined using the 
relative percent survival (RPS), antibody production levels, and carrier status of Y. 
ruckeri and gene expression. The results showed that ammonium sulphate was success-
fully used for Y. ruckeri inactivation and demonstrated further potential for bacteria 
inactivation using this method for commercial fish vaccines. Additionally, the serum 
humoral antibody levels did not correlate with the RPS and were not a good marker of 
protection of the fish against Y. ruckeri infection. The prevalence of asymptomatic 
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carriers was low. The gene expression was consistent with previous successful use as a 
biomarker of vaccine success in Atlantic salmon against Y. ruckeri. 
In the second experiment, the vaccine efficacy was assessed when ammonium sulphate 
inactivated bacterin was combined with hyperosmotic infiltration in vaccination. The 
results showed that ammonium sulphate vaccinated fish with hyperosmotic infiltration 
had significantly better survival than the unvaccinated fish with 25.6% higher in the 
RPS. It has demonstrated that hyperosmotic infiltration could improve protection of a 
vaccine against Y. ruckeri for Atlantic salmon and has the potential to be used with 
other bacterin-based immersion vaccines. 
The vaccine efficacy using single dip and double dip immersion vaccination at first 
feeding was tested to determine potential of protection against the early outbreaks of 
yersiniosis in the hatchery stage. There was no significant difference in the survival of 
salmon regardless of vaccination. In addition, expression levels of IgM gene were not 
different between the unvaccinated fish (control) and other two groups of vaccinated 
fish. This suggested that the vaccine did not work with the small fry that were vaccinat-
ed twice at 0.13 g and 1 g (2 dips) and single vaccinated at 1 g size. 
This thesis provided further understanding into different methods of immersion immun-
isation to yersiniosis in Atlantic salmon. Ammonium sulphate was successfully used for 
Y. ruckeri inactivation in vaccine production. The minimum fish size for the earliest
vaccination by immersion needs to be investigated further. 
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1.1. IMMUNE RESPONSE OF TELEOSTS 
The immune system of fish is similar to higher vertebrates and protects fish from threats 
such as bacteria, parasites and viruses (Lieschke & Trede, 2009; Uribe et al., 2011). The 
thymus, kidney and spleen are considered the primary lymphoid organs in teleosts 
(Zapata et al., 2006). The thymus is located near the gill cavity and is responsible for the 
production and proliferation of T-cells (Koppang et al., 2010). The kidney is the largest 
site of haematopoiesis and is the equivalent of the bone marrow in vertebrates (Zapata et 
al., 2006). The spleen is involved in haematopoiesis, represents the major peripheral 
lymphoid organ in jawed vertebrates showing erythropoiesis and thrombopoiesis 
activity (Rombout et al., 2005) and is involved in antigen capture (Press & Evensen, 
1999). Mucosa associated lymphoid tissue (MALT) includes gut-associated lymphoid 
tissue (GALT), skin-associated lymphoid tissue (SALT), and the more recently de-
scribed  gill-associated lymphoid tissue (GIALT) (Salinas et al., 2011). The GALT 
includes the lamina propia and the intraepithelial compartments, is scattered along the 
intestine. 
The immune response can be divided into innate immunity or non-specific immune 
response, and adaptive immunity or specific immune response. Innate immunity per-
forms an important role for survival from their early embryonic stages of life (Uribe et 
al., 2011). It is present in both vertebrates and invertebrates, is promptly available to 
combat infections and is the first line of defence against pathogens (Jørgensen, 2014). 
Innate immunity can be divided into a sensing arm and an effector arm. The sensing arm 
deals with how fish recognise pathogens while the effector arm deals with coordination 
of cellular responses to combat infection. Immune response includes cellular and 
humoral components and both are present in the sensing arm and the effector arm 
(Jørgensen, 2014). 
Myeloid cells, professional phagocytes that engulf and kill pathogens, include mononu-
clear and polymorphonuclear phagocytes, and are part of the innate immune response in 
vertebrates. The mononuclear phagocytes are efficient at presenting antigens to T-cells 
of the adaptive immune system (Jørgensen, 2014). Neutrophils are the main type of 
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polymorphonuclear phagocytes in fish (Hine, 1992). In fish, both macrophages and 
neutrophils are key inflammatory cells and are mobilized upon tissue injury or infection 
(Jørgensen, 2014). Melanomacrophages contain pigments including melanin. These 
cells can be found in the spleen, head kidney, as well as inflammations sites. They are 
assumed to be a part of the antigen-presenting cell system (Agius & Roberts, 2003). 
Phagocytes have two main tasks: phagocytosis and intracellular killing of pathogenic 
microorganisms. The pathogens are trapped into phagosomes or membrane-delimited 
compartments which then fuse with granules to form a phagolysosome. Within this 
phagolysosome, the pathogen is digested or effectively killed by the enzymes, antimi-
crobial peptides (AMPs) and reactive oxygen species (ROS) (Jørgensen, 2014). In 
addition, neutrophils can eliminate pathogenic microorganisms by the release of neutro-
phil extracellular traps (NETs) or antimicrobial proteins and extracellular structures 
composed of DNA (Brinkmann & Zychlinsky, 2007). The mononuclear fish phagocytes 
can express MHC class II and have the molecular machinery essential for antigen 
processing and presentation (Iliev et al., 2010; Wittamer et al., 2011). Natural killer 
(NK) cells are cytotoxic lymphocytes that can recognise infected and stressed cells and 
provide rapid responses to kill these cells by releasing inflammatory cytokines. The role 
of NK cells is similar to cytotoxic T-lymphocytes of adaptive immune responses in 
vertebrate but NK cells have the ability to recognise infected cells without need of 
major histocompatibility complex (MHC) and prior sensitisation (Jørgensen, 2014). 
Unlike the adaptive immune response, the innate immune response is available immedi-
ately to fight pathogenic agents and it responds to pathogen-associated molecular 
patterns (PAMPs). These PAMPs are detected by the soluble and cell-associated 
germline-encoded pathogen recognition receptors (PRRs) (Jørgensen, 2014). The innate 
immune receptors that recognise bacteria and virus in fish have been studied and some 
PRRs have been identified in fish including the toll-like receptors (TLRs), C-type 
lectins, RIG-I-like receptors, complement components and NOD-like receptors (Zhu et 
al., 2013). 
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Toll-like receptors (TLRs) represent one of the best studied PRRs with at least 16 types 
being reported in different fish species (Palti, 2011). Two primary subtypes of TLRs are 
identified in humans including type I (TLR1, 2, 4, 5, 6 and 10) which identify microbial 
lipids and sugars derived from different fungi and bacteria, while type II (TLR3, 7, 8 
and 9) mainly respond to nucleic acids derived from bacteria and virus. In fish, repre-
sentatives from both of these subtypes are found evenly with greater diversity of six 
more non-mammalian TLRs including TLR14 (similar TLR1 and 2), TLR19, 29, 21, 22 
and 23 (Oshiumi et al., 2003; Xiang et al., 2010). TLR5, a membrane-bound receptor in 
mammals, recognises bacterial flagella through their flagella component and it has been 
reported from rainbow trout (Onchorhynchus mikiss) (see Tsujita et al., 2004) and 
Atlantic salmon (Salmo salar) (see Tsoi et al., 2006). 
The NOD-like receptors (NLRs) and the RIG-I-like receptors (RLRs), two additional 
families of innate receptors, mainly related in bacterial or viral defence, have been 
found in fish (Laing et al., 2008). NOD1 and NOD2 are the best known of the NLR 
family members and these NLRs which are involved in inflammation, antibacterial and 
antiviral defences are present in fish in fish (Chang et al., 2011a; Sha et al., 2009). RIG-
I, MDA-5 and LGP2 are three members of the RLRs. These RLRs are involved in viral 
infection and has been found in rainbow trout, channel catfish (Ictalurus punctatus) and 
grass carp (Ctenopharyngodon idella) (see Chang et al., 2011b; Rajendran et al., 2012; 
Wang et al., 2012). 
Lectins, a group of sugar binding proteins, are important components of the innate 
immune system. They bind to carbohydrate structures from bacteria, virus, fungi and 
animals. In fish, diverse families of lectins recognise and agglutinate bacteria, virus, 
parasites and fungi. They also participate in downstream effector functions, such as 
agglutination and opsonisation of enteric bacteria (Vasta et al., 2011). C-type lectins 
(CTLs), members of the PRR family, have been identified in several fish species such 
as rainbow trout, zebrafish, common carp and turbot (Vasta et al., 2011). 
Most TLRs, NLRs and RLRs, not only bind to their PAMPs, but also lead to activation 
of NFkB and interferon regulatory factors (IRFs) (Kumar et al., 2011). NFkB activation 
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results in induction of DC maturation (CD80, CD83, CD86), enhanced inflammatory 
cytokine responses, chemokines and chemokine receptors (Janeway & Medzhitov, 
2002). IRFs activation mainly results in direct antiviral activity by interferon (IFN) 
induction, and also contributes to the host immune response (Kumar et al., 2011). 
Cytokines, small cell-signalling protein molecules, include interleukins and IFNs as 
immunomodulating agents (Jørgensen, 2014). About 35 interleukins are presently 
described in mammals and many direct homologues of these molecules are present in 
bony fish (Secombes et al., 2011). The cytokines IL-1β, TNF- and type IFNs are the 
best characterised fish cytokines, and are crucial cytokines secreted from innate immune 
cells (Jørgensen, 2014). The IL-1 family has a key role in the inflammatory responses 
and mammalian IL-1, IL-1β and IL-18 have been broadly characterised among their 
11 members (Barksby et al., 2007). In fish, only homologs to IL-1β and IL-18 have 
been identified, and IL-1β genes have been cloned from salmon (Ingerslev et al., 2006), 
trout (Zou et al., 1999), carp (Engelsma et al., 2003) and cod (Seppola et al., 2008). 
Salmonids have three different IL-1β genes (IL-1β1, 2 and 3) and expression of IL-1β 
has been found in the spleen, head kidney and gills (Ingerslev et al., 2006). 
A member of TNF family is TNF- which is involved in cellular signalling pathways in 
teleost (Wiens & Glenney, 2011). TNF- is a type II transmembrane glycoprotein that 
contains an extracellular C-terminal domain and a cytoplasmic tail. It is constitutively 
expressed in the gills and head kidney of rainbow trout and produced by activating 
macrophages and T lymphocytes (Laing et al., 2001). Important defence, produced 
during viral infections are IFNs which interfere with viral replication. Viral dsRNA or 
ssRNA act as PAMPs that are identified by PRRs and induce activation of transcription 
factors, followed by expression of type I IFNs which creates an antiviral state in the 
infected cell and alerts immune cells (Jørgensen, 2014). Atlantic salmon has at least 11 
IFN-genes with three subtypes (Sun et al., 2009). IFN has a direct activity against 
pathogenic viruses by inducing the expression of IFN-stimulates genes (ISGs) such as 
Mx, ISG15 and PKR (Caipang et al., 2003; Larsen et al., 2004; Zhu et al., 2008). 
Chapter 1 
General Introduction 
 
6 
 
The complement system, playing an important role in innate immunity, is made up of 
about 30 distinct plasma proteins and membrane-associated proteins, has ability to fight 
infections by opsonising pathogens and inducing a series of inflammatory responses 
(Janeway et al., 2001; Jørgensen, 2014). There are three different pathways of comple-
ment activation on pathogen surfaces including classical, alternative and lectin pathway. 
The classical pathway is commenced by the binding of C1b protein as a recognition unit 
that mainly recognises antibodies in the immune complexes. The lectin pathway is 
activated upon binding of the mannose-binding lectin (MBL) that is a serum protein, to 
sugar residual on the surface of the invading microorganism. The alternative pathway 
can be initiated by spontaneous activation of C3 binds to the surface of pathogen. The 
generation of C3 convertase, cleaves C3 to generate C3a and C3b, is the main function 
of all three pathways. C3b binds covalently to the invading pathogen and this pathogen 
was destroyed by phagocytes (Jørgensen, 2014).  
The adaptive immune system is triggered by some cells of the innate immune response 
such as macrophages and dendritic cells, when some pathogens still invade and estab-
lish infections (Mutoloki et al., 2014). This response has evolved early in vertebrate 
evolution, about 450 million years ago and it is found in all jawed vertebrates. The 
adaptive response relies upon antigen recognition and has exquisite specificity. It takes 
several days to weeks to develop but it improves and responds more effectively upon 
subsequent encounters as the same pathogen due to the ability to remember the invaders 
(Mutoloki et al., 2014). Improving the knowledge of the adaptive immune responses of 
fish is important for vaccine development (Warr, 1996). 
The lymphocytes, the key cell type of the adaptive immunity, including the B-cell and 
T-cells, are responsible for specificity of antigen recognition and initiation of the 
adaptive immune response (Magnadottir, 2010). Lymphocytes initiate from the bone 
marrow in mammals, have a lymphoid lineage that is different from the innate system as 
a myeloid lineage (Mutoloki et al., 2014). The humoral response involves B-cells while 
the cell-mediated response associates with T-cells (Magnadottir, 2010). In fish, both B-
cells and T-cells originate from the head kidney as there is no bone marrow (Mutoloki 
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et al., 2014). The head kidney is important for the maturation of B-cells, while the 
maturation of T lymphocytes occurs within the thymus (Salinas et al., 2011). In teleost 
fish, the head kidney and spleen are the main antigen trapping organs (Press & Evensen, 
1999). Melano-macrophage centers (MMC) in head kidney and spleen are structures of 
antigen trapping and primitive analogs of the germinal centers of higher vertebrates 
(Mutoloki et al., 2014). 
Immunoglobulins, important humoral components of the adaptive immune system, have 
been found in teleosts and include three classes. IgM is the primary antibody and is 
mainly produced by plasma cells and plasmablasts located in the head kidney (Bromage 
et al., 2004). This antibody isotype plays an important role as a marker for protection 
against bacterial and viral disease in fish (Mutoloki et al., 2014). The second isotype, 
IgD has been detected at the gene level in a number of fish species (Laurent & Perry, 
1990; Silverstone & Hammell, 2002), but only detected in channel catfish (Ictalurus 
punctatus) at the protein level as a monomer and lacking the variable region (Edholm et 
al., 2010). IgD-armed granulocytes were present. The third isotype, IgT is predominant-
ly found in the gut mucosa of several fish species. Pathogens affecting the gut induce 
IgT expression (Zhang et al., 2011). IgT is found in the mucus of the trout skin and in 
the gut mucosa (Sunyer, 2012) as well as gills (Chettri et al., 2012; Stevenson, 
1988), suggesting that IgT is important in mucosal immunity. However, the mecha-
nisms of protection from this antibody remain poorly understood with few studies being 
conducted on fish (Salinas et al., 2011). 
T lymphocytes or T cells play a central role in cell-mediated immune responses 
(Mutoloki et al., 2014). Depending on their T-cell receptors (TCR), T cells can be 
divided into β or  T-cells. The common traits like TCR, CD3, CD28 and CD45 are 
shared with mature T lymphocytes and these traits are involved in pathogen recognition 
and signalling or are on the surface molecules. Only antigens that are associated with 
MHC molecules or present on surfaces of other cells are recognised by T-cells. Depend-
ing on the function of cytotoxic or helper, T-cells are further divided into two groups. 
Cytotoxic T lymphocytes (CTLs), the effector cells of the cytotoxic response, are 
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involved in direct killing of abnormal or infected cells by secreting molecular to induce 
apoptosis. The target cells which display abnormal proteins or fragments of pathogens 
in association with the MHC-I molecules on their surface are identified by CTLs. CD3 
chains, CD28 and other T-cell co-inhibitory and co-stimulatory molecules were de-
scribed in several species (Boardman et al., 2012; Maisey et al., 2011; Øvergård et al., 
2009; Typical, 2006). However, the functional aspects of putative responses of different 
T-cell subsets still remains poorly understood. CTLs express CD8 molecules and TCR 
co-receptors which are involved in the MHC-I interaction of the cells. On the other 
hand, T helper (TH) cells act directly by secreting cytokines that regulate in the active 
immune response to a foreign threat (Mutoloki et al., 2014). A surface glycoprotein 
CD4 is expressed by TH cells, involved in the cellular interaction with MHC-II proteins. 
CD4 and CD4-like genes have been reported in many teleost fish (Dijkstra et al., 2006; 
Moore et al., 2009). Depending on the type of cytokine profile producing, TH cells are 
categorised into several regulator and effector subsets. TH1 cells, important in cell-
mediated responses, have been found in many fish species as IFN- (Zou & Secombes, 
2011). TH2 cells relate in humoral response, have not been functionally described in 
fish. TH17 cells, enhance responses to extracellular bacteria, secrete cytokines IL-17A to 
F in mammals. Five form of IL-17 has been found in zebrafish (Gunimaladevi et al., 
2006). TH17 cells also secrete IL-22 that was found in teleost fish. Another T-cell 
subset, TH22 secretes IL-22 but it is incapable of producing IL-17 (Eyerich et al., 2010). 
1.2. FISH VACCINATION 
Fish vaccines are an effective way to control fish diseases and increase fish production 
in aquaculture (Plant & LaPatra, 2011). More than 17 fish species have been vaccinated 
against more than six viral diseases and 22 different bacterial diseases in more than 40 
countries (Brudeseth et al., 2013). Vaccines have been used in salmon farming for 
approximately 30 years and the use of vaccines has increased salmon production. The 
use of oil-adjuvanted vaccines for controlling salmon disease reduced the use of antibi-
otics on Norwegian fish farms from 50,000 kg of antibiotics in 1987 to less than 2,000 
kg by 1997, while production increased from 50,000 tonnes to 350,000 tonnes 
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(Pridgeon et al., 2010; Sommerset et al., 2005). In other parts of the world, more than 
900 million fish have been vaccinated against enteric septicaemia of catfish (ESC) since 
2002 and this has given 13% higher fish survival in fish production (Pridgeon et al., 
2010). 
Fish vaccines can be administered by injection, immersion or orally. In general, intra-
peritoneal injection (i.p.) vaccination has the greatest efficacy and requires less vaccine, 
but can only be applied to larger juveniles and adult fish (more than 20 g fish). 
Anderson and Nelson (1974) showed that i.p. injection of a bacterin provided the most 
effective protection in terms of duration and relative percent survival (RPS) values. 
However, labour costs associated with i.p. vaccination are high and the vaccination can 
result in stress for the fish (Ototake et al., 1999). Furthermore, side effects associated 
with the injection site such as peritoneal lesions are of increased concern when oil based 
adjuvants are administered with i.p. vaccination (Skirtun et al., 2013). 
Immersion vaccination is a natural route of antigen entry that can overcome the disad-
vantages of delivery by injection (Moore et al., 1998). However, it often gives shorter 
duration of protection and needs a significantly greater volume of vaccine (Dixon & 
Becker, 2011). Dip and bath are two application methods of immersion vaccination 
(Komar et al., 2006). In dip vaccination, fish are immersed in a high concentration of 
vaccine for a very short time, normally 30 seconds to a few minutes. In bath vaccina-
tion, fish are immersed for a longer period of exposure (one to several hours) (Ross et 
al., 1966) in a low vaccine concentration. 
Fish vaccines against bacterial diseases can be made up of chemically or heat-
inactivated whole cells, inactivated soluble cell extracts, cell lysates, attenuated live 
cells, purified subcellular components, serum (for passive immunization) and mixtures 
of the components (Austin, 1984). However, the use of inactivated whole cells is the 
simplest and most common approach to producing vaccines for fish. Several methods 
for inactivating bacterial cells have been used and include the treatment with chemicals, 
such as chloroform, formalin, phenol, heat, sonication, and lysis with sodium dodecyl 
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sulphate (SDS) or with sodium hydroxide at pH 9.5 have tested for experimental fish 
vaccines (Austin, 1984). Formalin inactivation of cells is most commonly used for 
commercial fish vaccines (Austin, 1984; Sommerset et al., 2005). However, a few 
studies have compared different methods of inactivation. Amend et al. (1983) showed 
that chloroform inactivation of Y. ruckeri bacterins did not provide any advantage over 
formalin inactivation. The procedure of heat or formalin inactivation of bacterins may 
produce significant alterations of the antigens (Laurent & Hebibi, 1989; Roberts & 
Powell, 2003). Aeromonas salmonicida has been inactivated by chloroform, formalin, 
disruption with SDS, sonication and heat-killing for incorporation in fish vaccines and 
the results showed that formalin- inactivated cells of A. salmonicida fared better than 
their sonication and disruption with SDS counterparts (Antipa & Amend, 1977; 
Franklin, 1990; Katoh & Kaneko, 2003; Pritchard, 2003). 
Several studies have demonstrated ways to improve or enhance antigen uptake or 
vaccine efficacy in fish (Table 1.1). For example the use of ultrasound, considered as a 
new method of administrating vaccine to fish, has been shown to increase survival rates 
and antibody titres (Table 1.1, Navot et al., 2004; Navot et al., 2011; Zhou et al., 2002a; 
Zhou et al., 2002b). This method was as effective as intraperitoneal injection and 
required less volume of vaccine than bath immersion. In addition, hyperosmotic infiltra-
tion, which immerses the fish in 4.5% to 5.3% sodium chloride for a short period of 
time before vaccine administration, can enhance antigen or vaccine uptake (Table 1.1, 
Huising et al., 2003; Ototake & Nakanishi, 1992; Ototake et al., 1992). Furthermore, 
prolonged exposure to antigens during immersion vaccination can also increase particu-
lar uptake or vaccine effectiveness (Moore et al., 1998; Ototake et al., 1998; Ototake et 
al., 1999). Some immunostimulants such as trypsin, levamisole, propiscin and adjuvant 
are also used to elevate vaccine efficacy (Table 1.1). 
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Table 1.1 Methods to improved antigen uptake or vaccine efficacy in fish 
No Treatment Vaccine/Antigen Species (size) Other conditions 
(to, exposure) 
Effect References 
1 Ultrasound BSA Goldfish (Carassius 
auratus) 20-30 g 
25 ± 1 oC 
Ultrasound: 1 MHz, 
1 min to 3 MHz, 10 
min; 
2 or 0.4% BSA 
solution – 10 min 
↑ antigen transport through the skin 
↑ antibody production 
↓ antigen concentrations 
Navot et al. 
(2004) 
2 Ultrasound Vibrio alginolyticus Grouper (Epinephalus 
awoara) 20.5-22.5 g 
Salinity 33‰ 
28-30 oC 
Ultrasound: 35 kHz 
(frequency ) & 175 
mW/cm2 (intensi-
ty), 2-4 min 
↑ antibody titres 
↑ survival rates 
Ultrasonic vaccination = intraperitone-
al injection 
Zhou et al. 
(2002b) 
3 Ultrasonic 
immunization 
Mixed vaccine 
against Vibrio 
alginolyticus & V. 
anguillarum 
Sea bream (Pagrus 
major) 41.6 ± 5.2 g 
24-28 oC 
Ultrasound: 35 kHz 
(frequency) & 280 
mW/cm2 (intensi-
ty), 3-6 min 
↑ antibody titres 
↑ survival rates 
Ultrasonic vaccination = intraperitone-
al injection 
Reused the vaccine up to five times 
Zhou et al. 
(2002a) 
4 Ultrasound 
 
Aeromonas 
salmonicida 
 
 
Goldfish (Carassius 
auratus) 20 g 
25 ± 1 oC 
Ultrasound: 1 MHz 
frequency, 1 min 
↑ morbidity & cumulative protection 
↓ Petechiae 
↓ Ulcers 
Navot et al. 
(2011) 
5 Prolonged 
exposure period 
on soluble 
antigen uptake 
BSA 
 
 
Rainbow trout (On-
corhynchus mykiss) 
15.0 ± 3.4 g 
15 oC 
3 min – 48 hours 
↑ plasma BSA concentration Ototake et al. 
(1998) 
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6 Prolonged 
exposure 
BSA-conjugated 1 
µL fluorescent 
latex 
microspheres 
Rainbow trout (On-
corhynchus mykiss) 
1.5 ± 2.99 g 
15 oC 
3 min – 48 hours 
↑ particular uptake Moore et al. 
(1998) 
7 Prolonged 
exposure 
Vibrio ordalii Rainbow trout (On-
corhynchus mykiss) 
1.2 ± 0.5 g 
15 oC 
3 min – 24 hours 
↑ vaccine effectiveness Ototake et al. 
(1999) 
8 Hyperosmotic 
infiltration 
Bovine serum 
albumin (BSA) 
- Rainbow trout 
(Oncorhynchus 
mykiss) 18 ± 3 g 
- Yellowtail (Seriola 
quinqueradiata) 40 ± 8 
g 
- Chum salmon 
(Oncorhynchus keta) 
15-17 g 
- Tilapia (Oreochromis 
aureus) 156-157 g 
15 oC 
 
 
20 oC 
 
 
15 oC 
 
 
25 oC 
5.3% NaCl - 3 min 
↑ concentration of plasma BSA 
(freshwater -acclimatized fish) 
Ototake et al. 
(1992) 
9 Hyperosmotic Aeromonas 
salmonicida 
bacterin, A. 
salmonicida lipo-
polysacchride 
(LPS), Bovine 
serum albumin 
(BSA) 
Common carp (Cypri-
nus carpio) 
23 oC 
4.5% NaCl - 2 min 
 vaccine solution 
10 min 
 
↑ vaccine uptake 
↑ vaccine efficacy 
Huising et al. 
(2003) 
10 Hyperosmotic 
infiltration 
Bovine serum 
albumin (BSA) 
- Rainbow trout 
(Oncorhynchus 
mykiss) 18 ± 3 g 
15 oC 
 
 
BSA levels of seawater-acclimatized 
fish <  freshwater -acclimatized fish 
Ototake and 
Nakanishi (1992) 
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- Yellowtail (Seriola 
quinqueradiata) 40 ± 8 
g 
- Chum salmon 
(Oncorhynchus keta) 
15-17 g 
- Tilapia (Oreochromis 
aureus) 156-157 g 
20 oC 
 
 
15 oC 
 
 
25 oC 
5.3% NaCl - 3 min 
11 Immunostimu-
lants (QAC-
quaternary 
ammonium; 
ISK-short-chain 
polypeptide; 
Levamisole) 
Aeromonas 
salmonicida O 
antigen 
- Rainbow trout 
(Oncorhynchus 
mykiss) 20-30 g 
11 ± 2 oC 
Immunostimulant 
30 min  antigen 2 
min 
↑ neutrophil oxidative activity 
↑phagocytic uptake 
↑ protection levels 
Jeney and 
Anderson (1993) 
12 Combined 
immer-
sion/puncture 
immunization 
Streptococcus iniae Rainbow trout (On-
corhynchus mykiss) 4-
10 g 
15 oC ↑ vaccine efficacy 
↑ antigen uptake by skin 
↑ antigen delivery  to the kidney & 
spleen 
Nakanishi et al. 
(2002) 
13 Live Flavobac-
terium 
psychrophilum 
Flavobacterium 
psychrophilum 
Rainbow trout (On-
corhynchus mykiss) 
1.2-2.2 g 
10-11 oC 
Immersed 30 min 
↑RPS Lorenzen et al. 
(2010) 
14 Propiscin 
(anaesthesia) 
Yersinia ruckeri Rainbow trout (On-
corhynchus mykiss) 
30-40 g 
12 ± 1 oC ↑ Immunoglobulin secreting cell (ISC) 
↑ Antibody secreting cell levels (ASC) 
↑ Total Ig levels 
↑ Specific antibody  titres 
↓ Cumulative mortality rates 
Siwicki et al. 
(2002) 
15 Freund’s 
incomplete 
Edwardsiella tarda Japanese flounder 
(Paralichthys oliva-
22 oC ↑RPS 
↑ Specific serum antibodies 
Jiao et al. (2010) 
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adjuvant, 
aluminum   
adjuvant 
ceus) 10 g ↑ humoral immunity (aluminum) 
↑ humoral & innate cellular immunity 
(FIA) 
16 Trypsin Yersinia ruckeri Atlantic salmon 
(Salmo salar) 2 g 
15 oC ↑ survival rates 
↓ gill mucus lysozyme (6 weeks post 
vaccination challenge) 
Costa et al. (2011) 
17 Ocimum 
sanctum leaves 
Aeromonas 
hydrophila 
Tilapia (Oreochromis 
mossambicus) 25 g 
28 ± 1.5 oC ↑ antibody production 
↑ activation of neutrophils 
Logambal et al. 
(2000) 
18 Garlic, Allium 
sativum 
Aeromonas 
hydrophila 
Rohu (Labeo rohita)  
10 ± 2 g 
28 ± 1 oC ↑ RPS 
↑ lysozyme activity 
↑ Serum bactericidal activity 
Sahu et al. (2007) 
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The incorporation of vaccines into feed to enable oral delivery to fish is desirable 
because it is stress free; however, there are some disadvantages. These include: short 
term stability of vaccines when they are mixed with feed (Komar et al., 2006), the 
difficulty in determining the exact dose of antigen received by each fish (Plant & 
LaPatra, 2011), and the destruction of the vaccine in the fish’s digestive system (Polk et 
al., 1994). Oral immunisation has reported inconsistent results and relatively lower 
levels of protections than injection or immersion immunisation (Joosten et al., 1997; 
Newman, 1993). The first successful vaccination of trout against yersiniosis used a Y. 
ruckeri bacterin and was administered orally (Klontz, 1963).  Oral booster vaccination 
is preferred to improve duration of protection and reduce stressing the fish. This process 
protects the vaccine during gastrointestinal transit until uptake by the fish hindgut 
(Gomez-Gil et al., 1998; Joosten et al., 1995). Other factors such as vaccine concentra-
tion, the nature of the antigen (particulate or soluble), the length of vaccination time, the 
size of the fish and water temperature can have great impact on antigen uptake and 
vaccine efficacy (Ellis, 1977; LaFrentz et al., 2014; Nakanishi & Ototake, 1997; 
Valdenegro-Vega et al., 2013). 
Antigen uptake and duration of protection is affected by the duration of immersion and 
the antigen concentration (Nakanishi & Ototake, 1997). In general, shorter duration of 
immersion and higher dilutions tends to be less effective. For example, Tatner (1987) 
demonstrated that there were no significant differences in uptake of a 1/10 dilution of a 
vaccine at immersion times between five seconds to 10 minutes (Tatner, 1987). Howev-
er, at a 1/100 dilution, there was significantly lower uptake after 100 seconds to 10 
minutes of immersion compared to uptake following a two-hour immersion. Tatner and 
Horne (1985) reported that using very long exposures from one to six hours at very low 
vaccine concentrations (1:2000 and 1:5000) gave good protection. 
The size of fish at vaccination influences the duration and the level of immunity. 
Johnson et al. (1982) reported that 1 g was the minimum size that salmonids could be 
effectively immunized by immersion administration using Y. ruckeri and V. anguilla-
rum bacterins. In general, longer duration of protection occurred in larger fish, but 
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different responses were demonstrated in several species. In brook trout fry, the survival 
rate 60 days after an infectious pancreatic necrosis virus challenge was highest in two 
and three weeks post-hatch fry and decreased as fish increased in age or size after a 
single direct immersion (Bootland et al., 1990). The reason for this successful immun-
ization of a small size fish remains unknown. 
Water temperature has an effect on antigen uptake in immersion vaccination. Tatner and 
Horne (1983) reported that Vibrio anguillarum vaccine uptake decreased significantly at 
5 oC compared to 18 oC in rainbow trout. Similarly, there was significant protection 
of  vaccinated fish kept at 15 °C but no protective effect of vaccination was observed in 
rainbow trout reared at 5 °C and 25 °C using a bacterin of Y. ruckeri (Raida & 
Buchmann, 2008). 
Vaccine efficacy is commonly evaluated using relative percent survival (RPS) which is 
calculated according to a formula which depends on the relationship of survival of 
vaccinated fish to survival of unvaccinated controls, RPS = (1 - % mortality in vaccinat-
ed/% mortality in control) × 100 (Amend, 1981). RPS of 70% - 100% are common for 
immersion bacterin-based yersiniosis vaccines and depend on the infection challenge 
dose, the size of fish, the species of fish and the duration of booster or post-vaccination 
(Bridle & Nowak, 2014). An alternative method of evaluating vaccine efficacy 
measures antibody levels in fish serum after vaccination and post infection challenge by 
enzyme-linked immunosorbent assay (ELISA) (Chettri et al., 2015a). Correlation 
between protection and antibody levels, measured by ELISA, was used in evaluating the 
efficacy of vaccines in Atlantic salmon and Atlantic halibut (Hippoglossus hippoglos-
sus L.) (Bricknell et al., 1997; Gudmundsdóttir et al., 2003; Midtlyng, 1996). Immune 
gene expression was also suggested to be useful as a potential measure of vaccine 
success (Bridle et al., 2012). Changes in expression of 17 genes involved in an immune 
response, detoxification and repair was proposed as a biosignature to predict vaccine-
induced protection in immersion vaccination against yersiniosis of Atlantic salmon 
(Bridle et al., 2012). 
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Yersiniosis is a common problem in salmonid hatcheries. Since yersiniosis likely affects 
fish from very early stages of development, it is important to vaccinate as soon as 
possible. However, some studies have shown that fish below 1 g had a poor or delayed 
response to vaccination, possibly due to undeveloped of immune systems. Long term 
protection was only attained when fish above 2 g were vaccinated (Amend & Johnson, 
1980; Brudeseth et al., 2013). 
1.3. YERSINIOSIS IN ATLANTIC SALMON 
Yersinia ruckeri is a pathogen which causes significant losses in farmed salmonids 
(Tobback et al., 2009) and is the causative agent of both enteric red mouth disease in 
rainbow trout in the Northern Hemisphere (Tobback et al., 2009) and yersiniosis in 
Atlantic salmon (Salmo salar) in the Southern Hemisphere (Carson & Wilson, 2008). 
This pathogen is found in fish populations in Europe, North American, South Africa and 
Australia (Tobback et al., 2007). In Australia, there are two biotypes of Y. ruckeri, 
including serotype O1b (biotype 1) that is the predominant isolate in Atlantic salmon 
culture and serotype 01, non-O1b (biotype 2) which has been isolated on a few occa-
sions and only in Tasmania (Carson & Wilson, 2009). In addition to fish, Y. ruckeri can 
be found in freshwater invertebrates (crayfish), bird faeces, humans and mammals and 
can survive several months in the water (Siwicki et al., 2005). Y. ruckeri was initially 
isolated in the Hagerman Valley of Idaho, USA from rainbow trout (Oncorhynchus 
mykiss) in the 1950s (Ross et al., 1966). This bacterium is a Gram-negative rod with a 
diameter of approximately 0.75 µm and its length varies from 1.0 to 3.0 µm (Tobback et 
al., 2007). It belongs to the Enterobacteriaceae family, is oxidase negative, glucose 
fermentative and nitrate reductive (Ross et al., 1966). Y. ruckeri is positive for produc-
tion of β galactosidase, ornithine decarboxylase and lysine decarboxylase, whereas 
indole and H2S are not induced (Tobback et al., 2007). Y. ruckeri colonies, are off-
white, opaque, approximately 2 - 3 mm in diameter and appear after incubation for 48 h 
at 25 oC. The pathogen can be identified by a biochemical test (Carson & Wilson, 
2009), or serological tests with ELISA, immunofluorescence antibody technique 
(IFAT), agglutination test (Smith et al., 1987) or PCR assay (Gibello et al., 1999). 
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1.4. IMMUNE RESPONSE AGAINST YERSINIA RUCKERI 
In Atlantic salmon and rainbow trout, the innate and adaptive components of the 
immune response against yersiniosis have been investigated (Afonso et al., 1998; Bridle 
et al., 2011; Costa et al., 2011). A study on the innate immunity of Atlantic salmon 
affected by Y. ruckeri, demonstrated that lysozyme levels in gill mucus and serum 
bactericidal activity were increased after a Y. ruckeri challenge (Costa et al., 2011). 
Phagocytosis and killing of invading pathogens are important antibacterial defence 
mechanisms (Tobback et al., 2007). Phagocytes cells including neutrophils and macro-
phages engulf bacteria and kill them by stimulated production of reactive oxygen 
species (Tobback et al., 2007).  Afonso et al. (1998) found that numbers of macrophage 
peak at 5 days and neutrophil numbers peak at 24-48 hours post injection of live or 
killed Y. ruckeri in rainbow trout. The increase in macrophages and neutrophil numbers 
indicated phagocytes played a role in killing the bacteria. 
Host immune responses against Y. ruckeri have been studied at the transcription level 
using real-time RT-PCR to measure expression of immune-related genes (Bridle et al., 
2011; Raida & Buchmann, 2007; Raida & Buchmann, 2009). Cathelicidins, a family of 
antimicrobial peptides, have a critical role in the innate immune defence against inva-
sive bacterial infection (Zanetti, 2004). An in vivo challenge with Y. ruckeri showed the 
increased expression of cathelicidin 1 and 2 (asCATH1 and asCATH2) mRNA in 
Atlantic salmon (Bridle et al., 2011). This indicated that Atlantic salmon cathelicidins 
involve in an interplay between the innate and adaptive immune systems to respond 
more effectively to invading pathogens. In rainbow trout, an i.p. injection with Y. 
ruckeri elicited significantly increased gene expression of the pro-inflammatory cyto-
kines IL-1b, IL-6 and TNF-a, serum amyloid protein a (SAA) and down-regulation of 
complement factors (C3, C5 and factor B) (Raida & Buchmann, 2009). 
Immunoglobulins act as a critical part of the humoral adaptive immune response and 
antibody responses against Y. ruckeri in Atlantic salmon have been reported by various 
studies. IgM, the main immunoglobulin involved in systemic immune responses in 
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yersiniosis, has primarily been measured in serum of infected fish. Several research 
groups demonstrated that rainbow trout produce specific antibodies against Y. ruckeri 
following immersion vaccination (Anderson et al., 1979b; Olesen, 1991; Raida et al., 
2011). In contrast, Chettri et al. (2015a) found low serum antibody levels in vaccinated 
groups following immersion vaccination but much higher antibody levels after chal-
lenge which indicated priming of memory cells or B-cells from the initial immersion. 
IgT, also called IgZ was discovered in some species after analysis of the genomes of 
several teleost fish species (Danilova et al., 2005; Hansen et al., 2005). While the IgM 
isotype has a predominant role in systemic immune responses, the IgT isotype plays a 
specialised role in gut mucosal responses in rainbow trout (Xu et al., 2013; Zhang et al., 
2010). The gene expression of IgT in spleen has been shown to increase 10-fold after 
bath vaccination with Y. ruckeri bacterin (Raida & Buchmann, 2008). However, IgT 
was very weakly expressed or not regulated after intra-peritoneal vaccination with Y. 
ruckeri bacterin (Raida & Buchmann, 2007). IgT isotype has been characterised at the 
transcriptional level in Atlantic salmon (Tadiso et al., 2011). 
1.5. YERSINIOSIS IN FARMED ATLANTIC SALMON IN TASMANIA 
Atlantic salmon farming reached Australia in the mid 1980s (Darby, 2003). Australian 
salmonids production increased by 222% in value ($343 million) and by 179% in 
production volume (27,553 tonnes) from 2002-03 to 2012-13, and Tasmanian accounted 
for much of the strong growth (Stephan & Hobsbawn, 2014). In Tasmania, salmonids 
are the largest aquaculture species group, accounting for 90% of the volume and 94% of 
the value of  Tasmania’s aquaculture production in 2012-13 (Stephan & Hobsbawn, 
2014). 
Yersiniosis, or enteric redmouth disease (ERM), was first described in rainbow trout in 
1955 (Rucker, 1966). Yersiniosis is now widespread in farmed populations of a variety 
of salmonid and other species (e.g. eel, goldfish, perch, channel catfish, sole, sturgeon 
and turbot) in the USA, Europe and Australia (Carson & Wilson, 2009). Yersiniosis can 
affect all sizes of fish, but tends to occur as a less severe but more chronic form in larger 
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fish (Furones et al., 1993). When fish are exposed to Y. ruckeri, first mortality occurs 
approximately 4-8 days later, and can increase up to 50-70% during a typical 30-60 
days course of clinical infection (Busch, 1978). In most countries, yersiniosis is mostly 
a disease of rainbow trout, but in Australia it occurs predominantly in farmed Atlantic 
salmon (Bridle & Nowak, 2014; Carson & Wilson, 2009). The Hagerman strain, which 
causes ERM in rainbow trout, is exotic to Australia. (Bridle & Nowak, 2014). 
The first commercial yersiniosis vaccine was produced and licensed in 1976 as forma-
lin-killed whole cells of Y. ruckeri (see Bridle et al., 2012). In Australia, Yersinivac-B 
was developed by Department of Primary Industry Water and Environment Tasmania. 
Currently, Yersinivac-B is a commercial bacterin-based vaccine manufactured by MSD 
Animal Health and prepared from formalin-killed whole cells of Australian serotype 
O1b. It is used for immersion vaccination for most Tasmanian Atlantic salmon which 
until recently, were vaccinated once by bath immersion at 5 g. However, significant 
mortality due to yersiniosis still occurred and the greatest fish loss in a single Tasmani-
an hatchery occurred in 2007 when half a million vaccinated juvenile Atlantic salmon 
died (Costa et al., 2011). Currently, Tasmanian Atlantic salmon are vaccinated when 
they weigh 1-3 g and then again at 5 g, as a booster. However, mortalities due to Y. 
ruckeri still occur in farmed Atlantic salmon, particularly amongst small fish in hatcher-
ies. There is a need to develop better vaccination strategies to prevent mortality and 
morbidity in Atlantic salmon due to yersiniosis. 
1.6. AIM AND THESIS STRUCTURE 
This thesis focused on the improvement of yersiniosis vaccine efficacy for Atlantic 
salmon by using different administration methods of immersion immunisation. To 
address this objective, this thesis has the following aims: 
 Evaluate the effects of different inactivation methods of Y. ruckeri on the effica-
cy of single dip vaccines including formalin inactivation, ammonium sulphate 
inactivation, and pH-lysed then formalin treated inactivation. 
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 Compare hyperosmotic pretreatment with direct immersion in Atlantic salmon 
(Salmo salar) by using an ammonium sulphate inactivated Y. ruckeri whole-cell 
vaccine. 
 Investigate the vaccine performance of immersion vaccination with single dip 
and double dip vaccination of small fish at hatchery stage. 
This thesis has five chapters in total and is structured as follows: 
Chapter 1 (this chapter) contains a general introduction to the immune response of 
teleosts, general knowledge about fish vaccination, the pathogen studied, the immune 
response of fish against Yersinia ruckeri, the effects of yersiniosis with farmed Atlantic 
salmon in Tasmania and the thesis aims. 
Chapter 2 describes the results obtained from an experiment with different inactivation 
methods of Y. ruckeri where the vaccine efficacy of Atlantic salmon were determined at 
the relative percent survival (RPS), antibody production levels, carrier status of Y. 
ruckeri and gene expression. 
Chapter 3 describes the results of an experiment where the vaccine efficacy of ammoni-
um sulphate inactivated bacterin combined with hyperosmotic infiltration in vaccination 
was assessed. 
Chapter 4 describes the results of an experiment where the vaccine efficacy was investi-
gated with single dip and double dip immersion vaccination at first feeding. 
Chapter 5 is general discussion that assembles the most significant findings from the 
research chapters and connects them with current knowledge of the vaccine prevent 
yersiniosis. 
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2.1 INTRODUCTION 
The method of inactivation of the pathogen can have a significant effect on vaccine 
efficacy. Commonly used methods for inactivating bacterial cells include treatment 
with formalin, chloroform, lysis at pH 9.5, disruption with sodium dodecyl sulphate 
(SDS), heat and sonication (Austin, 1984). Formalin inactivated bacterial pathogens are 
most commonly used in vaccine preparations (Sommerset et al., 2005). Inactivation of 
bacteria by formalin influences the physico-chemical characteristics of surface antigens 
and may reduce protective efficacy against pathogenic bacteria (Tu et al., 2010). 
Inactivating Y. ruckeri by chloroform instead of formalin did not improve performance 
of a vaccine for rainbow trout (Oncorhynchus mykiss) (Amend et al., 1983).  However, 
Y. ruckeri bacterin prepared using pH lysed cells at pH 9.8 for 60 to 120 min had 
significantly improved efficacy (Amend et al., 1983). Ammonium sulphate, due to its 
kosmotropic properties, is commonly used to precipitate proteins (salting out) (Lovrien 
& Matulis, 2001). Ammonium sulphate has been used successfully to purify immuno-
genic proteins (Dzata et al., 1991), leukotoxin (Confer et al., 2006) and egg yolk 
immunoglobulin (Zhen et al., 2008). RNAlater used to preserve DNA, RNA and 
protein indefinitely when stored at -20 oC (Ambion, Life Technologies) is predominant-
ly saturated ammonium sulphate (70%). Due to the ability to precipitate and preserve 
antigens, ammonium sulphate has the potential as an inactivating agent for vaccine 
production. 
Vaccine efficacy is normally evaluated using the relative percent survival (RPS), 
cumulative percent mortality, antibody levels in fish serum after vaccination or expres-
sion of immune-relevant genes. The differential expression of specific genes linked to 
immune response, detoxification and repair were proposed as a biosignature for predic-
tion of induced protection in Atlantic salmon immersion-vaccinated against yersiniosis 
(Bridle et al., 2012). This proposed biosignature involved upregulation of 14 genes and 
downregulation of three others. According to the selection criteria proposed by Bridle et 
al. (2012), nine genes were suitable for evaluation and were selected for analysis (genes 
chosen described section 2.2.7). The nine genes were representative of highly upregu-
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lated genes, medium upregulated genes and downregulated genes. The hepcidin gene 
was selected as this peptide has potential activity against bacteria (Hu, 2008) and plays 
an important role in inflammatory response (Bao et al., 2005). It is also known to reduce 
splenomegaly and regulate iron homeostasis in mice in relation to immune functioning 
(Gardenghi et al., 2010). LIM and actin-binding protein are related to immunity and 
known to enhance bacterial internalisation in mammals (Pizarro-Cerdá & Cossart, 
2006). The fish virus induced TRIM protein is also related to diverse receptors of the 
host immune system and immune recognition of pathogens (Ellis, 1989). The expres-
sion of myelin and lymphocyte protein has been implicated and was also regulated in 
mammalian T-cell development (Frank, 2000). The bifunctional 3-phosphoadenosine 5-
phosphosulfate synthetase 2 gene was related to antioxidation activity and xenobiotic 
metabolism (Sahlmann et al., 2013). 
Even after vaccination, there is a possibility that some fish may harbor Y. ruckeri 
without showing clinical signs (i.e. asymptomatic carriers) (Bridle & Nowak, 2014; 
Fadaeifard et al., 2014). Rodgers (1992) found Y. ruckeri in the faeces of carrier fish 
two months after the disease outbreak. Y. ruckeri can remain viable in the kidney and 
the intestinal tract of the carriers and cyclical shedding of Y. ruckeri can occur. This can 
be exacerbated when fish are under stressful conditions, resulting in reinfection and 
spreading of yersiniosis (Busch & Lingg, 1975; Carson & Wilson, 2009). Further 
investigation of the presence of Y. ruckeri in vaccinated fish is needed to understand the 
reservoirs of the pathogen and risk factors for infection post-vaccination. 
This study was designed to determine the effects of different inactivation methods for 
Y. ruckeri on the efficacy after single dip bacterin administration. These methods 
included formalin inactivation, ammonium sulphate inactivation, and pH-lysed then 
formalin treated inactivation. This study aimed to investigate whether ammonium 
sulphate can be used for Y. ruckeri inactivation and can enhance protection compared 
to conventional formalin-killed and pH-lysed bacteria. Specific antibody levels were 
investigated as a measure of adaptive immune response in Atlantic salmon serum after 
administration of each bacterin preparation. The use of gene expression as a biosigna-
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ture of vaccine performance was evaluated. Spleen samples were analysed for presence 
of Y. ruckeri to determine carrier status. 
2.2 MATERIALS AND METHODS 
2.2.1 Fish 
Atlantic salmon (Salmo salar) with an average body weight of 5 g were provided by 
Salmon Enterprises of Tasmania (SALTAS) and held at the Aquaculture Centre, 
University of Tasmania. The fish were acclimated to laboratory conditions for five 
weeks prior to the experiment. Fish were held in flow through fresh water holding tanks 
of 4000 L at 15 oC and then moved to five 1500 L tanks after vaccination. Salmon were 
fed daily to satiation with a commercial diet (Skretting). Before vaccination and 
challenge, two to three fish from each treatment were lethally anaesthetised with clove 
oil (1 mL in 1 L of water) and checked for the presence of Y. ruckeri by culturing 
kidney samples on blood agar plates. All samples were negative of Y. ruckeri before 
vaccination and challenge. Water quality, including temperature, pH, ammonia, and 
chlorine, were assessed daily. This experiment was approved by the University of 
Tasmania Animal Ethics Committee (Approval Number A0012285). 
2.2.2 Preparation of bacterins 
A strain of Y. ruckeri, UTAS001, was obtained from the Institute for Marine and 
Antarctic Studies (IMAS), UTAS culture collection, and used to prepare the bacterin 
and challenge inoculation. A 300 mL brain heart infusion (Oxoid, England) starter 
broth was inoculated and shaken for 24 h, then 100 mL of this starter was added to a 10 
L Nalgene container and cultured for 46 h at room temperature. The number of bacteri-
al cells was counted using a Neubauer hemocytometer after inactivating the cells with 
10% formalin. 
Three different inactivation methods were used: formalin inactivation, ammonium 
sulphate inactivation then heat, and pH-lysed then formalin treated inactivation. Forma-
lin was added to 2 × 109 cells/mL to achieve a 0.3% final concentration for inactivation. 
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Ammonium sulphate inactivation was achieved by adding ammonium sulphate to the 
bacterin stock to achieve a 50% solution (1 kg ammonium sulphate into 2 L bacteria) 
and then adjusting the pH from approximately 7.2 to 5.2 with concentrated hydrochlo-
ric acid (HCl), as measured by a digital pH meter. This vaccine was then incubated at 
60 oC for 2 h. The pH-lysed experimental vaccine was prepared by adjusting the pH to 
10 and leaving the bacterial culture for 3 h before adjusting the pH from approximately 
10 to 7.4, and inactivating with 0.3% formalin. After the inactivation, a small sample of 
each bacterin was inoculated on both blood agar plates and a LB broth base (Sigma, 
USA) to confirm inactivity. The absence of any bacterial growth after 24 h indicated 
the sterility. The bacterins were stored at 4 oC until required. 
2.2.3 Vaccination 
One hundred and fifty fish (8 to 10 g) were used for each treatment. During vaccina-
tion, the fish were netted and dipped into a 20 L bucket containing 2 L of a 1:10 
dilution of one of the three vaccines for a period of 60 s (dipping 50 fish/time). After 
vaccination, the fish were dipped in water to remove excess vaccine. The control fish 
were dipped in water for 60 s with no added bacterin (150 fish). The positive control 
fish (125 fish) were vaccinated by intraperitoneal injection (100 µL/fish) with the 
formalin inactivated bacterin. All vaccine preparations started with the same concentra-
tion of bacteria. 
2.2.4 Challenge 
At 12 weeks post vaccination, fish from each treatment (n=75) were randomly selected 
and transferred to a challenge room and challenged with Y. ruckeri (9×105 colony 
forming units (CFU)/mL for 1 h) in air saturated 20 L buckets with fresh water at 15 
oC. The fish were then rinsed in fresh water and transferred into 200 L recirculating 
tanks (3 tanks per each of the five treatments). Moribund fish were removed and 
recorded daily until the end of the experiment. Relative percentage survival (RPS) was 
calculated, RPS = (1 – (% mortality/% control mortality)) x 100 at the end of the 
experiment (Amend, 1981). For moribund fish, bacteria were re-isolated from two to 
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three fish per treatment and identified for confirmation of cause of morbidity and 
disease. 
2.2.5 Sampling 
From each treatment, 10 fish were sampled before vaccination (time 0), at week 6 and 
at week 12 post-vaccination. Sampled fish were anaesthetised with clove oil (1 mL in 
15 L of water) and blood plasma was collected from the caudal vein using EDTA (pH 
8.0) as an anticoagulant. Due to undetectable antibody results of ELISA assay with 
blood plasma at week 6, blood serum was collected from whole blood without EDTA at 
week 12 post-vaccination after clot formation overnight at 4 oC. Plasma or serum was 
recovered by centrifuging at 5000 x g for 10 min at 4 oC and stored at -20 oC. Gills 
were collected and stored in an RNA preservation solution (25 mM sodium citrate, 10 
mM EDTA, 70 g ammonium sulphate/100 mL solution, pH 5.2) at 4 oC overnight 
before transfer to -20 oC. At the end of the experiment, 20 survivors were sampled from 
each treatment to determine carrier status using Quantitative real-time RT-PCR 
(qPCR). 
2.2.6 Blood analysis 
2.2.6.1 Indirect Enzyme-linked immunosorbent assay (ELISA) 
ELISA was used to detect the presence of specific antibodies in the blood serum using 
lipopolysaccharide (LPS) extracted from Y. ruckeri as a coating antigen. For LPS 
extraction, 350 mg (wet weight) formalin-inactivated cells of Yersinia ruckeri were 
placed into a 50 mL tube and then centrifuged at 3,000 x g, 4 oC for 30 min. The 
supernatant was discarded and then 2.2 mL of distilled water was added to the pellet. 
The pellet was then transferred to a 15 mL tube and 0.4 mL of 100 mM Tris-HCl (pH 
8.0), 0.4 mL of 0.5 M MgCl2 and 1.0 mL of 8% Triton X-100 were added, and the tube 
then heated in boiling water for 10 min. After cooling, the resulting mixture was 
centrifuged at 15,000 x g (max, fixed angle) for 15 min and then the precipitate (or 
pellet) was washed once with 4 mL of 10 mM Tris-HCl (pH 8.0)-10 mM MgCl2. The 
tube was then centrifuged at 15,000 x g (max, fixed angle) for 15 min and the superna-
Chapter 2 
Effects of inactivation methods of Yersinia ruckeri on the efficacy of dip vaccination 
 
     28 
tant discarded. Then 1mL each of distilled water, 0.2 M EDTA (pH 8.0), 2 M NaCl and 
8% Triton X-100 was added to the precipitate and mixed well. This suspension was 
incubated at 37°C for 60 min with gentle agitation, and then centrifuged at a fixed 
angle at max (15,000 x g) for 15 min. The supernatant was removed and put in a fresh 
15 mL tube. To this tube, 0.6 mL of 1 M MgCl2 was added and 1 mL of 100% ethanol 
was then followed by the drop-wise addition. This tube was then incubated at 37°C for 
60 min. After incubation, this sample was immediately centrifuged at 20 oC maximum 
at a fixed angle (18,514 x g) for 60 min and the supernatant discarded. The transparent 
precipitate was washed once with 4 mL of 10 mM Tris-HCl (pH 8.0)-10 mM MgCl2, 
and centrifuged again at 20 oC maximum at a fixed angle (18,514 x g) for 5 min. 
Finally, the LPS pellet was weighed, resuspended in distilled water and then used for 
ELISA. 
ELISA was used to detect the presence of specific anti-Yersinia LPS antibodies in the 
blood serum. The monoclonal anti-salmonid Ig (H chain) antibody was supplied by 
Cedarlane Laboratories Ltd, product number CLF004HP, and all wash buffers were 
prepared according to their protocols. 96-well flat bottom ELISA plates (Iwaki, Science 
Product Dept., Asahi Glass Co., Ltd.) were coated by 100 µL dilution of 10 µg/mL LPS 
antigens, Y. ruckeri,  in a coating buffer and left overnight at 4 oC. Three washes with a 
low salt wash buffer removed the coating solution. Free binding sites were blocked by 
2 h incubation with 3% skim milk at 18 oC and then washed three times with a low salt 
wash buffer. After washing, 100 fold dilutions of serum in PBS were added in dupli-
cates at 100 µL/well. A positive standard sample which consisted of a pool of sera from 
fish immunised with Yersinivac-B by i.p. from a previous experiment, aliquoted and 
maintained at -20 °C. This standard with the dilutions of 1:100, 1:200, 1:400, 1:800, 
1:1600 and 1:3200 were added to “standard wells” in triplicate at 100 µL/well. Two 
wells of every plate were blanks. Plates were then sealed and incubated in a plate 
shaker for 2 h at 18 oC. A high salt wash buffer was used to wash the plates three times 
with 5 min incubation at room temperature for the last wash. 100 µL of reconstituted 
monoclonal anti-salmon Ig – HRPO (Horseradish Peroxidase) conjugated (Cedarlane 
Laboratories Ltd, product number CLF004HP) with 500 fold dilutions was added to 
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each well and incubated at 18 oC for 1 h. After incubation, the plates were washed five 
times with a high salt wash buffer, with 5 min incubation at room temperature for the 
last wash. Chromogen was then added (100 µL/well of TMB One Solution, Promega 
G7431) to each well and after 10 min incubation at room temperature, a stop solution 
(100 µL/well of 1 M sulphuric acid) was added. The plates were read at 450 nm 
(Spectra Rainbow Thermo, Xread Plus V4.04, Serial 9340045) after being shaken for 
10 seconds. Absorbance values were referred to an arbitrary unit (AU) of 100 AU for 
100 fold dilutions, 50 AU for 200 fold dilutions, 25 AU for 400 fold dilutions, 12.5 AU 
for 800 fold dilutions, 6.25 AU for 1600 fold dilutions and 3.125 AU for 3200 fold 
dilutions. A standard curve was generated by using the four parameter logistic curve 
(SigmaPlot 11.0) and plotting the AU of the hyper-immune serum against absorbance 
and converted absorbance sample values to AU. 
2.2.6.2 Bacterial agglutination 
Agglutination activity against Y. ruckeri in fish serum samples was determined using a 
modified version of a method described by Roberson (1990). Firstly, 25 µL of sterile 
PBS was added to all wells of a 96 well U-bottomed microtiter plate. Then 25 µL of 
serum were added to the first column of this plate with duplicate rows. A twofold 
dilution series was then made across each row (from 1:2 dilution to 1:4096 dilution). A 
25 µL aliquot of the bacterial suspension (1×109 cells/mL) that was fixed in 0.5% 
formalin, centrifuged at 2000 x g at 4 oC for 10 min, and washed three times with 
sterilised phosphate buffered saline (PBS) was then added to all wells. The plate was 
shaken for 30 seconds and incubated overnight at 18 oC. A circular mat above settled 
bacteria represented a positive agglutination, while a non-turbid solution with a central 
settle pellet indicated a negative agglutination. The agglutination titre was determined 
as a reciprocal of the highest serum dilution showing agglutination. 
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2.2.7 Quantitative Real-time PCR Analysis 
A total of 20 fish including 10 fish of naive unvaccinated (week 0) and 10 fish of 
ammonium sulphate inactivation vaccine (week 6), were used to analyse the expression 
of nine genes of interest (Table 2.1). 
Table 2.1 List of nine genes chosen for gene expression analysis in the gills of 
Atlantic salmon before and after ammonium sulphate inactivated vaccine 
Accession number Gene 
EG929305 Uncharacterized protein KIAA1033 
DY699380 LIM and actin-binding protein 1 [Salmo salar] 
DY729690 Hepcidin 
EG859007 E3 ubiquitin-protein ligase Itchy 
CA054083 Immunoglobulin mu heavy chain [O. mykiss] 
DW565729 Fish virus induced TRIM protein [O. mykiss] 
CB496376 Myelin and lymphocyte protein 
EG912256 Bifunctional 3-phosphoadenosine 5-phosphosulfate synthe-
tase 2 
EG779342 Thioredoxin interacting protein [Salmo salar] 
2.2.7.1 RNA extraction, DNA decontamination and reverse transcription 
Gill samples (5-10 mg, approximately 0.5 cm x 0.5 cm) were removed from RNA 
preservation reagents and cells were lysed using 400 µL of extraction buffer (4 M urea, 
1% SDS and 2 X PBS) supplemented with 5 µL (5 units) of proteinase K. The resulting 
suspension was cooled on ice for 5 min and incubated at room temperature (RT) for 60 
min with occasional mixing by vortex. Protein was removed by precipitation with the 
addition of 1mL of TRI-Reagent (Sigma-Aldrich) followed by 150 µL of BCP (bromo-
chloropropane) and centrifuged at 12,000 x g for 15 min at 4 oC. RNA was then 
precipitated from the supernatant with the addition of one volume of isopropanol with 
pink-pellet paint co-precipitate (1:500 Pink: Iso) and centrifugation at 16,000 x g for 10 
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min at RT. The nucleic acid pellet was then washed twice with 75% ethanol and eluted 
in 40 µL of water with 20 mM DTT at 55 oC for 5 min. Removal of residual genomic 
DNA was achieved by treatment of the purified RNA with 2 units of Baseline-ZERO™ 
DNase (Epicentre) for 30 min at 37 oC. Total RNA concentration was measured by 
using a Qubit® 2.0 Fluorometer (Life Technologies) and Quant-iT RNA assay kit 
(Invitrogen, VIC, Australia). The integrity and purify of RNA was examined by running 
in 1% agarose gel using RNA EZvision dye (Amresco, Sydney, Australia) as per 
manufacturer’s instructions. RNA was reversely transcribes using a 50 µM of Oligo 
dT18 primer (0.8 µL per sample typical stock, 1 µL of 10 mM dNTP, 2 µL of 5 X RT 
buffer, 0.25 µL of RNAse inhibitor, 6.25 µL of molecular grade water and 0.5 µL of 
reverse transcriptase) and random Hexomer 50 ng/µL (0.2 µL per sample typical stock). 
Reactions were performed in a C1000 thermo cycler (Bio-Rad, Australia) with 20 µL 
reaction volumes containing 2 µg of total RNA extraction (9 µL samples). The reactions 
were run under the following conditions: 65 oC for 10 min, 42 oC for 50 min, 70 oC for 
15 min and 12 oC indefinitely. 
2.2.7.2 cDNA Template 
Following cDNA generation, five standards were created, 3 µL of each sample was 
pooled into a single eppendorf tube and diluted with 2 volumes of molecular grade 
water to create standard 1. The other four standards were made by serially diluting in 4-
fold dilution with water (i.e. 30 µL into 90 µL of water, the highest to the lowest). The 
remaining samples were diluted with water in 4-5 folds (i.e. 73 µL of H20 added to the 
17 µL of the remaining samples after the standard pooling, making the total volume of 
90 µL).  All samples and standards were then transferred to the cDNA plate and held at 
4 oC for later use. 
2.2.7.3 Real-Time qPCR for Gene Expression Analysis 
A single master mix was prepared for all samples and standards by mixing 3.96 µL of 
water, 0.02 µL of 100 mM forward primer, 0.02 µL of 100 mM reverse primer and 5 
µL of 2X polymerase/syber mix (i.e. SensiFast) per reaction. This master mix was then 
transferred to a qPCR plate (9 µL/well) in a Bio-Rad iQ5 Real-Time machine (Bio-
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Rad) by using a multichannel pipette. Next, 1 µL of cDNA template from a stock plate 
was transferred into this qPCR plate and mixed by using a pipette. A film seal was 
applied to the plate and the plate was then short spun to 500 g at 4 oC. A run protocol 
and the plate setup were selected using real-time software. A generic protocol for 
SensiFast was:  94 oC for 2 min, then 95 oC for 5 sec, 55 oC for 20 sec and 72 oC for 10 
sec for 40 times and then for melting curve 95 oC for 1 min, 55 oC for 1 min and 55 oC 
+ 1 oC/10 sec for 36 times, until 90 oC. An amplification efficiency of the standards 
should generate between 85-105% with an R2 higher than 0.98. This real-time qPCR 
was used to measure expression of  the nine different genes of uncharacterized protein 
KIAA1033, LIM and actin-binding protein, hepcidin, E3 ubiquitin-protein ligase Itchy, 
immunoglobulin mu heavy chain, fish virus induced TRIM protein, myelin and lym-
phocyte protein, bifunctional 3-phosphoadenosine 5-phosphosulfate synthetase 2 and 
thioredoxin interacting protein.  When the amplification efficiency of the standards of 
the genes generated between 85-105%, mRNA expression levels were determined by 
qBase Plus software (Biogazelle, Belgium) using the mean expressions of two refer-
ence genes – elongation factor 1a (EF1a) and b-actin. qBase Plus software was also 
used for analyse the qPCR data including statistical analysis (ANOVA) and fold 
change of difference genes. 
2.2.8 Carrier status analysis 
2.2.8.1 Total nucleic acid (TNA) extraction from spleens 
A 10-20 mg sample of spleen was removed from RNA preservation reagents and TNA 
extracted by addition of 600 µL of extraction buffer (4 M Urea, 1% SDS, 0.2M sodium 
chloride, 1 mM sodium citrate, pH 8.2) supplemented with 5 µL of proteinase K. The 
resulting suspension was incubated at 37 oC overnight with occasional mixing by 
vortex. Protein, cellular debris, and detergent were then removed by centrifugation in 
300 µL of 7.5 M ammonium acetate at 16,000 x g for 5 min at 18 oC. Nucleic acids 
were then precipitated from the supernatant by addition of an equal volume of isopro-
panol with pink-pellet paint co-precipitate (1:500 Pink:Iso) and centrifugation at 16,000 
x g for 10 min at RT. The nucleic acid pellet was then washed twice with 70% ethanol 
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and resuspended in 200 μL elution buffer [molecular-grade water containing 10 μm 
TRIS-HCL and 0.05% Triton X100 (Sigma- Aldrich)] by incubation at 55 oC for 10 
min. 
2.2.8.2 PCR for carrier status 
The PCR master mix consisted of 5 µL of 2 X My TaqTM HS DNA Polymerase mix 
(Bioline), 0.4 µL each of forward primer of Y. ruckeri (YrF) and reverse primer of Y. 
ruckeri (YrR) (400 nM of each), 0.1 µL of Y. ruckeri (Yr) probe (100 nM), 2.1 µL of  
PCR water (Bioline BIO-37080) and 2 µL of TNA sample. The PCR amplification 
program was as follows: 95 oC for 3 min, then 95 oC for 10 sec and 60 oC for 30 sec for 
44 cycles. 2 µL of PCR water was used as no template control. Primers and probe used 
for PCR were YrF (5'-AAC CCA GAT GGG ATT AGC TAG TAA-3'), YrR (5'- GTT 
CAG TGC TAT TAA CAC TTA ACC C -3') and Yr probe (Taqman) (5'-
AGCCACACTGGAACTGAGACACGGTCC-3'). 
2.2.9 Statistical analysis 
Survival was analysed using SigmaPlot 11.0, Kaplan-Meier Survival Analysis. Multi-
ple comparisons were performed using the Holm-Sidak method including adjustment of 
the P value to avoid type I errors. A one-way ANOVA (Analysis of Variance) was used 
for the analysis of results from quantification of Y. ruckeri cells mg-1 of spleen between 
the control fish and three other vaccinated groups, and if significant followed by a 
Turkey’s post hoc test to identify where significant differences occurred among treat-
ment means. Difference in percentage of Y. ruckeri carriers was tested for significance 
using Chi-square analysis. The results were considered significant when P < 0.05. The 
Microsoft Excel 2010 Data Analysis Package was used to analyse correlation coeffi-
cients between antibody level and agglutination activity of serum of each vaccinated 
groups according to Pearson’s method. Data input and statistical analysis were 
achieved using SPSS 22.0 software (SPSS Inc., USA). 
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2.3 RESULTS 
Fish mortalities were observed from day 3 to day 14 post challenge. The negative 
control fish had a lower survival rate (50%) than the fish vaccinated with ammonium 
sulphate inactivated bacterin (96.7%), pH-lysed inactivated bacterin (90.62%), and 
formalin inactivated bacterin (92.71%) and the positive control (100%) (Figure 2.1). 
Survival of fish vaccinated with ammonium sulphate inactivated bacterin was not 
significantly different from either pH-lysed inactivated bacterin (P =0.0968) or forma-
lin inactivated bacterin (P = 0.233).  
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Figure 2.1 Effects of three different inactivation methods for Y. ruckeri bacterin prepa-
rations administered by immersion (ammonium sulphate inactivation, formalin 
inactivation and pH-lysed then formalin inactivation) compared to intraperitoneal 
injection with bacterin and unvaccinated negative control group on survival of Atlantic 
salmon after disease challenge. Twelve weeks post-vaccination, 63 Atlantic salmon 
from the injection group and 91 to 96 fish for each of the four other groups of were 
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challenged by immersion with 9 × 105 CFU/mL of Y. ruckeri. Different letters indicate 
significant differences (Survival analysis, SigmaPlot 11.0, P < 0.05) 
The unvaccinated fish showed a significantly lower survival rate than the three vac-
cinated groups of fish and the positive control fish. The mortality in vaccinated fish 
varied from 3.30% to 9.38%, giving the RPS of the ammonium sulphate vaccinated 
fish, formalin vaccinated fish and pH-lysed then formalin treated vaccinated fish at 
93.4%, 85.4% and 81.3% respectively (Table 2.2). 
Table 2.2 Protection of Atlantic salmon following vaccination using bacterin 
produced by different inactivation methods 
Treatments 
Number 
of fish 
Specific 
mortality 
Survival 
(%) 
Mortality 
(%) 
RPS 
(%) 
Control 96 48 50.00 50.00 0 
Injection 63 0 100 0 100.0 
Ammonium sulphate + 
heat 91 3 96.7 3.30 93.4 
pH-lysed + formalin 96 9 90.62 9.38 81.3 
Formalin 96 7 92.71 7.29 85.4 
Only the injection vaccinated fish showed measureable serum antibody levels (week 
12). Titre ranged from 2.2 to 89.1 AU, with the mean value of 13.69 ± 27.02 AU. No 
antibody titre was seen in the unvaccinated fish (control) or immersion vaccinated fish 
regardless of the vaccine used. 
Bacterial agglutination was evident at a titre ranging from 4 to 128 only in the positive 
control fish (injection vaccination). No agglutination was seen in the unvaccinated fish 
serum (control), the ammonium sulphate vaccinated fish serum, the formalin vaccinat-
ed fish serum or the pH-lysed then formalin treated vaccinated fish serum. 
There was no correlation between antibody level and agglutination activity of serum in 
Atlantic salmon against Y. ruckeri in the injection inactivation group with R2 of 0.0014 
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(Figure 2.2). The lack of relationship (P > 0.05) between average antibody titre and 
agglutination in the injection inactivation group was confirmed by using the non-
parametric Spearman r test, with a Spearman r of 0.298. 
 
Figure 2.2 The correlation between antibody level and agglutination activity of serum in 
Atlantic salmon against Y. ruckeri in injection inactivation group 
Gene expression results showed that four genes were excluded from further analyse due 
to their amplification efficiency of the standards outside 85-105%. These four genes 
were uncharacterised protein KIAA1033, E3 ubiquitin-protein ligase Itchy, immuno-
globulin mu heavy chain, and thioredoxin interacting protein. The results of five of 
differentially expressed genes in the gills when the unvaccinated fish (week 0) and the 
vaccinated fish (week 6) of the ammonium sulphate inactivated vaccine were compared 
are shown in Table 2.3. All five genes were up-regulated in the fish vaccinated with the 
ammonium sulphate inactivated vaccine six weeks post-vaccination. 
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Table 2.3 List of differentially expressed genes in the gills of Atlantic salmon 
showing significant upregulation (ANOVA P < 0.05) before and after vaccination 
(week 0 and week 6) of the ammonium sulphate group before Y. ruckeri challenge. 
Arrows indicate the direction of the fold change 
Genes Differential regulation 
Week 0 vs Week 6 
P value 
LIM and actin-binding protein 1 3.2  0.0001 
Hepcidin 2.5  0.0060 
Fish virus induced TRIM protein 4.1  0.0072 
Myelin and lymphocyte protein 2.5  0.0003 
Bifunctional 3-phosphoadenosine 5-
phosphosulfate synthetase 2 
3.4  0.0001 
The presence of Y. ruckeri in the spleen of surviving fish of five treatments at week 15 
is shown in Table 2.4. The unvaccinated control fish had the highest number of fish that 
were carriers of Y. ruckeri (7/20) and the lowest number was in the groups vaccinated 
with the ammonium sulphate inactivated bacterin (1/20) and the formalin inactivated 
bacterin (1/20). The number of bacteria ranged from 0.01 x 102 to 0.83 x 102 Y. ruckeri 
cells mg-1 of spleen and there was no significant difference in numbers between the 
control fish and the four other groups (P > 0.05). 
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Table 2.4 Presence of Y. ruckeri cells in the spleen by qPCR at 15 week post vac-
cination (surviving fish). No significant difference was observed between the 
control fish and the four other groups (P > 0.05) 
Treatment Organ 
Number of samples 
positive for Y. ruckeri 
Y. ruckeri number 
mg-1 (mean ± SD) 
Control Spleen 7/20 83 ± 189 
Injection Spleen 4/20 11 ± 31 
Ammonium sulphate Spleen 1/20 1 ± 6 
pH-lysed Spleen 2/20 36 ± 112 
Formalin Spleen 1/20 12 ± 54 
2.4 DISCUSSION 
The present work showed high protection by three kinds of inactivated vaccines for 
Atlantic salmon against yersiniosis. There was a significant difference between unvac-
cinated fish (control) and the other three vaccinated groups including ammonium 
sulphate inactivated bacterin, pH-lysed inactivated bacterin, and formalin inactivated 
bacterin. The ammonium sulphate inactivated group had 8-12% higher RPS than either 
the pH-lysed inactivated group or the formalin inactivated group. However, no signifi-
cant difference was found in these groups. Formalin is currently the most commonly 
used inactivation method in vaccine preparations. The cross-linking of proteins caused 
by formalin treatment may have a negative effect on the immunogenicity of some 
protein antigens or obscure epitopes (Kaminski et al., 2014; Klockenbusch & Kast, 
2010; Sompuram et al., 2004). Ammonium sulphate is the most commonly used salt for 
salting out proteins or protein purification and can preserve potential antigens by 
precipitating potentially damaging proteases and nucleases as used in RNAlater, a 
sample preservation reagent that is 70% ammonium sulphate. Using ammonium 
sulphate to inactivate Y. ruckeri to produce vaccines may be more efficient compared to 
formalin inactivated bacterin due to the lack of cross-linking of proteins and may 
increase the shelf-life of the bacterin because of its precipitation of potentially damag-
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ing proteases. To the best of my knowledge, ammonium sulphate has not been used 
previously for inactivation of bacteria for fish. Therefore, potential impacts or concerns 
over fish welfare by using this vs other methods need to be further investigated. The 
value of ammonium sulphate for fish vaccines in yersiniosis should be further investi-
gated. 
The vaccine that was inactivated by pH-lysis then formalin treated gave good protec-
tion (RPS = 81.3%) in this experiment. It has been shown that bacterins prepared from 
pH-lysed cells help to release O-antigen which significantly increases the potency of Y. 
ruckeri bacterins (Amend et al., 1983). Fish vaccine efficacy can be enhanced through 
the use of specific O-antigen extractions (Anderson et al., 1979a) as they improve 
humoral and cellular defence mechanisms in fish (Anderson & Jeney, 1991). However, 
the present study did not show a significant difference in the protection between pH-
lysed inactivated group and the common formalin inactivated whole-cell vaccine. 
Blood plasma at six week post vaccination was collected and antibody levels against Y. 
ruckeri were measured but there was no detectable antibody level in any of the groups. 
Therefore, at 12 week post vaccination serum was sampled following some studies on 
antibody response in Y. ruckeri vaccine (Chettri et al., 2015a; Jaafar et al., 2015; 
Soltani et al., 2014). This change in method for blood collection would not change the 
detection sensitivity because when I used blood plasma, there was no antibody level in 
all groups (data not show). Fish serum antibodies represent a specific humoral defence 
by neutralising bacterial toxins and prohibiting bacterial adherence or incursion into 
non-phagocytic host cells (Ellis, 1999). Antibodies against Y. ruckeri were found only 
in the injection vaccinated fish that had the highest protection against Y. ruckeri. The 
present results were consistent with the results of Chettri et al. (2015a) that found 
serum antibody levels of vaccinated and unvaccinated groups before challenge were 
low and not significantly difference after immersion vaccination with a Y. ruckeri 
vaccine. Similarly, although Kumari et al. (2013) found that antibody levels against 
Aeromonas salmonicida in turbot (Scophthalmus maximus) were high in injection 
vaccinated fish, there were virtually no antibody in immersion vaccinated fish at 28 d, 
60 d, 120 d and 180 d post treatment. Previous studies have shown that trout produce 
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specific antibodies against Y. ruckeri following immersion vaccination (Anderson et al., 
1979b; Olesen, 1991; Raida et al., 2011). However, detectable antibody titre was absent 
in unvaccinated fish (control) and all immersion vaccinated fish in the present study. 
The immunological mechanism behind the protective effect of the Y. ruckeri immersion 
vaccination remains unknown. Chettri et al. (2015a) reported that antibody levels were 
not detected after immersion vaccination with a Y. ruckeri vaccine but the antibody 
reactions were significantly elevated after challenge in these groups. One of the possi-
ble explanations could be the immersion vaccination induced priming of memory cells 
or B-cells that are involved in the protection after exposure to live bacteria (Chettri et 
al., 2015a). Anti-Yersinia LPS antibodies were used for coating that could not account 
for any lack of antibody response detected because whole cells were used first for 
coating and the results showed no lack of antibody response detected (data not show). 
Some studies suggested that coating of whole cells to microtiter plates can cause 
inconsistent results in ELISA (Poxton, 1995; Thirumalapura et al., 2006). 
The agglutination results showed that only injection vaccination elicited agglutination 
titres and no agglutination was observed in any of the salmon vaccinated by immersion. 
This result was consistent with the results of serum antibody levels in the present study. 
In a previous study, bacterial agglutination was the highest in the serum of Atlantic 
salmon that were injected with Yersinivac-B and no agglutination was evident in the 
other salmon, including non-vaccinated fish (control), single dip vaccinated fish, bath 
vaccinated and orally vaccinated fish (Tonkes, 2010). Serological data and the results 
of the RPS in the immersion vaccines confirmed that there was no correlation between 
the level of protection against Y. ruckeri infection and the level of serum antibodies. In 
rainbow trout, majority of particles were remaining within skin and gill tissues for up to 
24 days post-exposure demonstrated that local immune responses had an important role 
in the protection from pathogens following immersion immunisation (Moore et al., 
1998). Ohtani et al. (2014) showed that Y. ruckeri bacterin was initially taken up via 
gill lamellae around 30 seconds following immersion immunisation in rainbow trout. 
The mechanism of protective immunity against Y. ruckeri should be further investigat-
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ed to identify if this is due to a localised immune responses or a cell-mediated immune 
response. 
Following the success of the ammonium sulphate inactivated vaccine from the chal-
lenge results, this study used the real-time PCR to determine gene expression of five 
genes of interest that were involved in the immune response of Atlantic salmon in 
immersion vaccination against yersiniosis. These genes were chosen from 17 genes 
which were used as surrogates to measure protection of a specific vaccine-induced 
biosignature that could be used to predict the vaccine success after vaccination but 
before the Y. ruckeri challenge (Bridle et al., 2012). These five genes were up-regulated 
in the fish after six weeks of vaccination with the ammonium sulphate inactivated 
vaccine. The up-regulated of hepcidin, LIM and actin-binding protein, and fish virus 
induced TRIM protein was consistent with the results of Bridle et al. (2012). Hepcidin 
was significantly up-regulated in expression post infection with Y. ruckeri in rainbow 
trout (Chettri et al., 2012). The results of this study suggest hepcidin has a role in the 
antibacterial defences of Atlantic salmon against yersiniosis (Bao et al., 2005; Hu, 
2008). In contrast, myelin and lymphocyte protein and the bifunctional 3-
phosphoadenosine 5-phosphosulfate synthetase showed the opposite results to those 
reported previously (Bridle et al., 2012). The different regulation of these genes may be 
due to different method of measurement. Our study confirmed three up-regulation 
genes (more than 2.5 fold change) may be used to predict efficacy of Y. ruckeri vac-
cine. It would be useful to continue investigate the other genes studied by Bridle et al. 
(2012) to increase our understanding of immune response genes as surrogate of protec-
tion in predict vaccine success. 
In this study, Y. ruckeri cells were observed in the spleen of surviving fish three weeks 
after challenge. The spleen is a major secondary immune organ where plasma cells, 
lymphocytes and macrophages develop (Ellis, 1989) and is known as an important site 
of immune cell flux and bacterial replication during Y. ruckeri infection (Welch & 
Wiens, 2005; Wiens et al., 2006). A small number of positive fish with Y. ruckeri with 
a small number of Y. ruckeri cells present in three vaccinated groups compared to the 
non-vaccinated group (control). This may indicate that the vaccinated fish are protected 
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from the disease caused by Y. ruckeri by not immune to infection. Further studies are 
required to investigate the reinfection status of Y. ruckeri with the correlation of Y. 
ruckeri cells in fish organs after vaccination. 
In conclusion, the present study has contributed to a better understanding of how 
different inactivation methods of Y. ruckeri influence vaccine efficacy in Atlantic 
salmon. Ammonium sulphate can be used to precipitate, preserve and purify protein. In 
this study, ammonium sulphate was successfully used for Y. ruckeri inactivation and 
demonstrates potential for bacteria inactivation for commercial fish vaccines. Using 
ammonium sulphate can overcome the disadvantages of cross-linking of proteins 
created during formalin inactivation and as a result produce more efficient vaccine for 
fish. Additionally, this study showed that there was no correlation between the level of 
serum humoral antibodies and the RPS in protecting the fish against Y. ruckeri infec-
tion. The prevalence of asymptomatic carriers was lower in vaccinated fish. The gene 
expression results contributed to our understanding of immune response genes as 
surrogate of protection in Atlantic salmon against Y. ruckeri. 
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3.1 INTRODUCTION 
Immersion vaccination is a natural route of antigen entry and has certain advantages 
over injection vaccination due to reduced stress on the fish, the convenience of vaccinat-
ing a large number of fish at one time and low labour costs (Moore et al., 1998; 
Nakanishi & Ototake, 1997). The most common forms of immersion vaccination used 
are direct immersion, hyperosmotic infiltration and spray. Hyperosmotic infiltration that 
immerses the fish in a hypertonic solution such as sodium chloride or urea for a short 
period of time followed by immersion in the vaccine, increased the vaccine uptake and 
enhanced the efficacy of several vaccines (Huising et al., 2003; Ototake & Nakanishi, 
1992; Ototake et al., 1992). However, some authors have reported contradictory find-
ings showing that hyperosmotic infiltration did not enhance antigen uptake or immune 
response (Anderson et al., 1979b; Tatner & Horne, 1983). Huising et al. (2003) showed 
that antigen-specific serum immune response was not detected following either hyper-
osmotic immersion or direct immersion but the mucosal antibody response following 
hyperosmotic immersion was stronger and lasted longer than that detected after direct 
immersion. In coho salmon (Oncorhynchus kisutch), serum agglutinins were induced 
five weeks after a hyperosmotic immersion treatment with either an inactivated suspen-
sion of Aeromonas salmonicida, Vibrio anguillarum, or a combination of the vaccines 
(Antipa & Amend, 1977). In contrast, Anderson et al. (1979b) found no specific anti-
body titres with either hyperosmotic immersion or direct immersion with Y. ruckeri 
bacterin in rainbow trout (Salmo gairdneri). Hyperosmotic infiltration may also cause 
stress and damage to the fish skin and gills therefore counteracting the potential im-
proved efficacy afforded by the procedure (Nakanishi & Ototake, 1997). 
Huising et al. (2003) showed that hyperosmotic immersion vaccination immediately 
increased the Na+ and Cl- concentration and osmolality in plasma but the homeostatic 
equilibrium was quickly restored when the fish was returned to fresh water. Laurent and 
Perry (1990) also reported a stress response in trout by the slight increase in plasma Na+ 
and Cl- level three hours after hyperosmotic immersion. A fundamental knowledge 
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about the effects of hyperosmotic pretreatment on vaccination with the effect on gills of 
Atlantic salmon is unclear. 
Chloride cells in the gills are the primary site of ion absorption and secretion and play a 
pivotal role in adaptation to seawater and freshwater conditions (Katoh & Kaneko, 
2003; Pritchard, 2003) It has been reported that changing salinity had affected the 
density of chloride and mucous cells (Laurent & Perry, 1991). Laurent and Hebibi 
(1989) reported that after transfer to artificial seawater, the density of filamental chlo-
ride cells was increased more than twofold in rainbow trout. In the smoltification 
process during which Atlantic salmon adapt to the changing water salinity from fresh-
water to seawater, the main physiological change is an increase in the number of 
chloride cells in the gills (Silverstone & Hammell, 2002). The chloride cells help to 
maintain osmoregulatory balance in hyperosmotic environments by pumping of sodium 
out of the blood. The proliferation of chloride cells in the gill epithelium involved in the 
elevation of plasma cortisol concentrations (Perry, 1997). Both the salinity increase or 
the infection resulted in increase of mucous cell number (Roberts & Powell, 2003). In 
sockeye salmon (Oncorhynchus nerka), the number of gill filament mucous cells was 
increased after transfer to seawater (Franklin, 1990). Hyperosmotic pretreatment may 
involve changing the number of chloride and mucous cells in the gills but no study has 
shown these effects of hyperosmotic immersion on fish gills. 
Little is known about the effects of hyperosmotic infiltration on the efficacy of bacterin 
against yersiniosis in Atlantic salmon. This study has been undertaken to compare 
hyperosmotic infiltration with direct immersion in an ammonium sulphate inactivated Y. 
ruckeri whole-cell vaccine that has previously been used successfully to vaccinate 
Atlantic salmon (chapter 2 results). The serum antibody levels and the gill structure 
were also investigated in this current study. This study aimed to conclude that hyperos-
motic pretreatment may provide protection-effective over direct immersion 
immunisation in Atlantic salmon against Y. ruckeri. 
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3.2 MATERIALS AND METHODS 
3.2.1 Fish 
Atlantic salmon (Salmo salar) weighing 2 g were provided by Salmon Enterprises of 
Tasmania (SALTAS) and were acclimatised to laboratory conditions for one week prior 
to the experiment. The fish were held in 1000 L tanks with a semi-recirculating fresh-
water at 15 oC and were then moved to five 250 L net enclosures after vaccination. Fish 
were fed daily to satiation with a commercial diet (Skretting) and starved for 24 h prior 
to sampling. Fish kidneys were sampled from two or three fish per treatment and 
cultured on blood agar plates to confirm the absence of Y. ruckeri before vaccination. 
pH, ammonia and chlorine were checked daily to maintain water quality. This experi-
ment was approved by the University of Tasmania Ethics Committee (Animal Ethics 
Number A0012285). 
3.2.2 Preparation of bacterins 
Formalin inactivated bacterin and ammonium sulphate inactivated bacterin were pre-
pared as described in section 2.2.2.  
3.2.3 Vaccination 
Two hundred fish were used for each of five treatments which included ammonium 
sulphate inactivated bacterin, formalin inactivated bacterin, ammonium sulphate inacti-
vated bacterin with hyperosmotic infiltration (all dip immersion), and positive and 
negative control groups which received formalin-inactivated bacterin by intraperitoneal 
injection or no vaccine respectively. For the vaccination, the fish were dipped in a 3 L 
bucket containing a 1:10 dilution of one of the three vaccines for a period of 60 s with 
constant aeration (dipping 50 fish/time). The fish vaccinated using hyperosmotic 
infiltration were dipped in a 4.5% NaCl solution for 3 min and then in ammonium 
sulphate inactivated bacterin for 60 s. After each vaccination the fish were dipped in 
freshwater to remove excess vaccine. The control fish were dipped in freshwater only 
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for 60 s (200 fish). The positive control fish (203 fish) were vaccinated by intraperito-
neal injection (50 µL/fish) with the formalin inactivated bacterin. 
3.2.4 Challenge 
At 12 weeks post vaccination, fish (11 g) from each treatment (n=90) were challenged 
with Y. ruckeri (2.5 × 108 colony forming units (CFU)/ mL for 1 h) in air saturated 20 L 
buckets with fresh water at 15 oC. Fish were challenged and mortality was monitored as 
described in section 2.2.4. The experiment ended at 15 days after challenge and RPS 
was used to evaluate vaccine efficacy. 
3.2.5 Sampling 
From each treatment, 10 fish were sampled before vaccination (time 0) and at 12 weeks 
post-vaccination. Due to the small size of the fish, blood was only collected at week 12 
post-vaccination. Sampled fish were anaesthetised with clove oil (1 mL in 1 L of water) 
prior to blood collection from the caudal vein using a 0.3 mL syringe and a 31 gauge 
needle, and placed into a 0.6 mL eppendorf tube. Blood samples were allowed to clot 
overnight at 4 oC. Following centrifugation at 500 x g for 10 min at 4 oC serum was 
recovered and stored at -20 oC. In addition, gills from five fish from each treatment 
were sampled after vaccination (week 0). These gills were fixed in Davidson’s fixative 
(3 parts 95% ethanol, 2 parts 37-40% formaldehyde, 1 part glacial acetic acid and 3 
parts filtered sea water) for at least 48 h before being transferred to 70% ethanol for 
storage and later histological examination. 
3.2.6 Blood analysis 
3.2.6.1 Serum ELISA 
ELISA for detection the presence of specific anti-Yersinia antibodies in the blood serum 
were performed as described in section 2.2.6.1. 
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3.2.6.2 Bacterial agglutination  
Due to the limited volume of blood obtainable from less than 10 g fish, pools of serum 
were used for the agglutination assay. Two pools of five fish from each treatment were 
used for analysing agglutination titres. Agglutination titres against Y. ruckeri in fish 
serum were determined as described in section 2.2.6.2. 
3.2.7 Histology 
Davidson’s fixed gills were transferred to 70% ethanol until routinely processed for 
histology. This processing included dehydration in a graded ethanol bath (80%–
100%), clearing in xylene, paraffin-embedding, sectioning at 5 μm on microtome 
(Microm, Heidelberg, Germany), and then staining with haematoxylin and eosin using 
an automatic staining machine (Shandon, Linistain GLX, Waltham, USA). Finally, 
these sections were mounted on glass slides with distrene–plasticiser–xylene (DPX). 
These sections were then examined for mucous cells and chloride cells by using light 
microscope at magnifications of 40 – 400 X. Mucous cell and chloride cell counts were 
carried out on 5 fish for each treatment excluding the injection group (400 X magnifica-
tion). Five well-orientated filaments were randomly selected and 4 inter-lamellar units 
(ILUs) from each filament were randomly chosen (total 20 inter-lamellar units per fish). 
The number of mucous cells and chloride cells present on each ILU were counted and 
the results averaged for each treatment. 
3.2.8 Statistical analysis 
Survival was analysed by using SigmaPlot 11.0, Kaplan-Meier Survival Analysis, with 
the multiple comparisons performed using the Holm-Sidak method including adjust-
ment of the P value to avoid type I errors. The analysis of results from serum antibody 
levels, mucous cells and chloride cells were performed by using a one-way ANOVA. It 
was also used to compare differences between treatments as appropriate, and if signifi-
cant followed by a Turkey’s post hoc test to identify where significant differences 
occurred among treatment means. The results were considered significant when P < 
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0.05. Data input and statistical analysis were achieved using SPSS 22.0 software (SPSS 
Inc., USA). 
3.3 RESULTS 
Fish mortalities started at day 4 post challenge. The negative control fish had a lower 
survival rate (21.1%) than the fish vaccinated with ammonium sulphate inactivated 
bacterin (35.6%), formalin inactivated bacterin (35.6%), ammonium sulphate inactivat-
ed bacterin with hyperosmotic infiltration (46.7%) and the positive control (97.8%) 
(Figure 3.1). However, excluding the i.p. injected positive control, the ammonium 
sulphate inactivated bacterin with hyperosmotic infiltration was the only treatment 
shown to be significantly different from the negative control (unvaccinated fish) (P = 
0.008). 
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Figure 3.1 Effects of immersion vaccination using different bacterin preparations 
(formalin-inactivated, ammonium sulphate inactivation, ammonium sulphate inactivated 
bacterin with hyperosmotic infiltration) on survival of Atlantic salmon after disease 
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challenge. Twelve weeks post-vaccination, five groups of 90 Atlantic salmons each 
were challenged by immersion with 2.5 × 108 CFU/mL of Y. ruckeri. Different letters 
indicate significant differences (Survival analysis, SigmaPlot 11.0, P < 0.05) 
The mortality in vaccinated fish varied from 53.3% to 64.4%, giving the RPS of the 
ammonium sulphate vaccinated fish with hyperosmotic infiltration 32.4%, ammonium 
sulphate vaccinated fish 18.3% and formalin vaccinated fish 18.3% (Table 3.1). 
Table 3.1 Protection of Atlantic salmon following vaccination using bacterin 
produced by different inactivation methods and hyperosmotic treatment methods 
Treatments 
Number 
of fish 
Specific 
mortality 
Survival 
(%) 
Mortality 
(%) 
RPS (%) 
Ammonium sulphate 90 58 35.6 64.4 18.3 
NaCl + Ammonium 
sulphate 
90 48 46.7 53.3 32.4 
Formalin 90 58 35.6 64.4 18.3 
Injection 90 2 97.8 2.2 97.2 
Control 90 71 21.1 78.9 0 
There was no serum antibody titre at week 12 in any of the immersion vaccinated 
groups or negative control fish. 
Bacterial agglutination was evident at a titre ranging from 4 to 8 only in the positive 
control fish (injection vaccination). No agglutination was seen in the unvaccinated fish 
serum (control), the ammonium sulphate vaccinated fish serum, ammonium sulphate 
vaccinated fish serum with hyperosmotic infiltration and formalin vaccinated fish 
serum. 
The means of chloride cell counts (Figure 3.2) were significantly different between 
treatments (P < 0.001). Post hoc tests revealed that chloride cell counts were significant-
ly higher in formalin vaccinated fish compared to that of unvaccinated fish (3.88 ± 0.03, 
3.26 ± 0.09 chloride cells ILU-1, respectively, P < 0.001). Chloride cell counts in 
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unvaccinated fish (control) (Figure 3.2) were not significantly higher compared to 
ammonium sulphate vaccinated fish with or without hyperosmotic infiltration (P > 
0.05). 
C
on
tr
ol
Fo
rm
al
in
N
aC
l +
 A
m
m
on
iu
m
A
m
m
on
iu
m
0
1
2
3
4
5
Treatments
M
e
a
n
s 
o
f
c
h
lo
r
id
e
 c
e
ll
s
 
Figure 3.2 Chloride cell counts per interlamellar unit (ILU) for Atlantic salmon (mean ± 
S.E.) 
The mean of mucous cell counts (Figure 3.3) were significantly different between 
treatments (P < 0.001). Post hoc tests revealed that mucous cell counts were significant-
ly higher in ammonium sulphate vaccinated fish with hyperosmotic infiltration (1.10 ± 
0.09 mucous cells ILU-1) compared to that of unvaccinated fish (0.57 ± 0.04 mucous 
cells ILU-1, P < 0.001). Mucous cell counts in formalin vaccinated fish (0.73 ± 0.03 
mucous cells ILU-1) and ammonium sulphate vaccinated fish without hyperosmotic 
infiltration (0.52 ± 0.04 mucous cells ILU-1) were not significantly different compared 
to that of the unvaccinated fish (P > 0.05). 
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Figure 3.3 Mucous cell counts per interlamellar unit (ILU) for Atlantic salmon (mean ± 
S.E.) 
3.4 DISCUSSION 
The survival rate of the fish vaccinated with the ammonium sulphate inactivated bacte-
rin with hyperosmotic infiltration was greater by 25.6% and significantly different than 
the survival rate for unvaccinated control fish. Vaccination with the other bacterin 
preparations resulted in no significant difference in survival post challenge to the 
unvaccinated control group except for the group injected with the bacterin which had 
survival which was significantly higher than all other groups. These results strongly 
suggest that hyperosmotic infiltration can improve protection afforded by immersion 
vaccine against Y. ruckeri for Atlantic salmon. Previous research has shown that hyper-
osmotic infiltration, where vaccinated common carp (Cyprinus carpio) were immersed 
in 4.5% NaCl for two minutes before vaccine administration, enhanced the vaccine 
uptake or vaccine efficacy (Huising et al., 2003). Increased antigen uptake was shown 
for rainbow trout (Oncorhynchus mykiss) (see Fender & Amend, 1978), channel catfish 
(Ictalurus punctatus) (see Thune & Plumb, 1984) and increased vaccine protection in 
a 
a 
b 
a 
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sockeye salmon (Oncorhynchus nerka) (see Antipa et al., 1980). Amend and Fender 
(1976) suggested that hyperosmotic infiltration had a hydrating effect on membranes of 
organs such as gills or the lateral line canal and it allows the antigen to infiltrate into 
fish more easily. Therefore, Atlantic salmon in the hyperosmotic infiltration group in 
this study may have taken up more Y. ruckeri bacterin compared to the non-
hyperosmotic infiltration group which resulted in higher protection. Ototake et al. 
(1996) had quantified antigen uptake in hyperosmotic infiltration (HI) and direct 
immersion (DI) by using labelled bovine serum albumin (BSA) in rainbow trout. The 
results showed that BSA concentrations in HI group were significantly higher than 
those of the DI group for the tissues of skin, gills and intestine. This method may apply 
for further studies to quantified Y. ruckeri uptake in hyperosmotic pretreatment and 
direct immersion. The relative percent survival (RPS) of three modes of vaccine appli-
cation in this study did not meet the suggested 60% for effective protection (Amend, 
1981), possibly due to the high challenge dose (2.5 × 108 CFU/mL). The size of the fish 
used in this study was smaller than the fish used in Chapter 2. They were 2 g at vaccina-
tion and were challenged 12 weeks later with the fish size around 11 g. Therefore, it 
seems that the fish size would have been contributed to the high mortality after chal-
lenge of three immersion immunisation groups. Furthermore, a study by Brudeseth et al. 
(2013) showed that fish of less than 2 g weight have a poorly developed immune 
competency and this may be another reason for the poor vaccine efficacy. 
Gills are the major route of antigen entry in bath immunisation (Bowers & Alexander, 
1981; Kawahara & Kusuda, 1988; Ohtani et al., 2014). This study has shown that the 
gills of ammonium sulphate vaccinated fish with hyperosmotic infiltration did not 
contain different number of chloride cells, but showed significantly higher numbers of 
mucous cells compared to unvaccinated fish. Chloride cells perform the roles of acid-
base balance, ionic regulation and gas transfer (Perry, 1997). Perry (1997) also showed 
that the proliferation of the chloride cells is beneficial to ionic regulation, however, it 
impedes respiratory gas transfer by causing a thickening of the blood-to-water diffusion 
barrier. There was not a significant difference in the number of chloride cells in the 
hyperosmotic infiltration group compared to control group in this study. This suggests 
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that the hyperosmotic pretreatment had no adverse effects on the fish. Mucous cells 
contain polyanions, mucins composed of glycoproteins that can prevent toxicant entry 
into the gill epithelium by trapping toxicants (Perry & Laurent, 1993). Despite being 
beneficial in reducing toxicant entry, the consequence of mucous cell proliferation may 
be an increase in the distance for gas exchange along the secondary lamellae and 
causing hypoxic conditions (Ultsch & Gros, 1979). The number of mucous cells in fish 
gill of the hyperosmotic infiltration group was significantly higher than in the gills of 
fish from the unvaccinated group. However, as the hyperosmotic pretreatment is short 
in duration (3 minutes), the fish may recover when they get back to their normal water 
environment. Further studies with more replication at different time points are needed to 
determine the effects of hyperosmotic infiltration on the chloride cells and mucous cells. 
Before Y. ruckeri challenge (week 12 post vaccination), no antibodies against Y. ruckeri 
could be detected in the three groups: the immersion vaccinated fish, the positive 
control fish (injection vaccination) and the negative control fish (unvaccinated fish) 
using ELISA. The present results were consistent with a recent research has shown that 
serum antibody levels reacting with Y. ruckeri in rainbow trout before the challenge 
were not significantly different in injection vaccinated fish, immersion vaccinated fish, 
and unvaccinated control fish (Chettri et al., 2013). There was no antibody titre in 
injection vaccinated fish when the challenge results showed an RPS of 97.2%. There 
was no correlation between the level of serum antibody production and the level of 
protection afforded by immersion vaccine. 
The agglutination results at 12 weeks post vaccination showed that injection vaccination 
elicited an adaptive immune response. However, agglutination was not observed in any 
of the salmon vaccinated by immersion. While this does not mean a lack of an adaptive 
immune response in these fish, when combined with the low titres in the i.p. injected 
fish, it does suggest that the immune system of 2 g Atlantic salmon may not be fully 
developed. It is also possible that agglutination antibody titres may have been produced 
and measurable prior to 12 weeks post vaccination. Therefore, measurement of antibody 
titres at earlier time points in post vaccination should be included in future research. 
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Furthermore, measurable serum agglutination or serum anti Y. ruckeri antibodies in 
immersion vaccinated Atlantic salmon was not necessary for protection (Tonkes, 2010). 
In conclusion, the present study has demonstrated that hyperosmotic infiltration can 
improve protection of a vaccine against Y. ruckeri for Atlantic salmon. It confirmed that 
ammonium sulphate can be used for Y. ruckeri inactivation and has the potential to be 
used to inactivate bacteria for other bacterin-based immersion vaccines. 
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4.1 INTRODUCTION 
Y. ruckeri can affect fish of all ages, but is most acute in salmonids during their hatch-
ery stage. Yersiniosis may appear in Atlantic salmon smolt, particularly 3 - 6 weeks 
post transfer to marine grow-out sites and the number of fish affected is typically 
between 0.1 and 0.75% per week (Carson & Wilson, 2009). Clinical signs of yersiniosis 
in juvenile salmonid fish include changed behaviour, with fish moving sluggishly or 
swimming near the surface of water and an abnormal increase in mortality. Atlantic 
salmon with yersiniosis may also have darkening of the body. Other clinical signs of 
yersiniosis include unilateral or bilateral exophthalmos, haemorrhagic blood spots on 
the iris of the eye, haemorrhage with reddening along the lateral line, at the base of the 
pectoral and pelvic fins and on the head region. Enteric red mouth disease in rainbow 
trout is caused by Y. ruckeri infection and is characterised by subcutaneous haemor-
rhage in the throat and mouth (Carson & Wilson, 2009; Tobback et al., 2007). 
The first commercial ERM vaccine was produced and licensed in 1976 as formalin-
killed whole cells of Y. ruckeri (see Bridle et al., 2012). In Tasmania, Atlantic salmon 
are vaccinated once by bath immersion at 5 g. After a study (Costa et al., 2011) which 
found that vaccination using the dip form of immersion resulted in a higher level of 
protection compared to bath vaccinations, the Tasmanian salmonid industry converted 
to use more dip vaccinations. Fish are usually vaccinated when they weigh 1-3 g and 
then again at 5 g, as a booster. The ontogeny of immune system in salmonids has been 
studied to identify protective immune mechanism in early life stages and the ways that 
they cope with the pathogens in the natural aquatic environment. In rainbow trout, carps 
and zebrafish, the maturation of humoral immune responses is delayed until one or two 
months (Zapata et al., 2006). No indication in the gene expression of TCR-, RAG-1 
and IgM (BCR) of 0.15 g Atlantic salmon fry indicated they had undeveloped immune 
response (Gadan et al., 2013). Johnson et al. (1982) suggested that only fish of about 2.5 
g can achieve long term protection post vaccination and fish less than 1 g had a poor 
response to vaccination because of a poorly developed immune response. However, 
mortality still occurs at hatcheries and it appears that yersiniosis affects fish from very 
early stages of development. The ability to vaccinate fish and protect them against Y. 
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ruckeri as early as possible would be an obvious advantage. Thus vaccine application 
strategies in early life stages of Atlantic salmon need further investigation. The aim of 
this study was to investigate the vaccine performance of immersion vaccination and 
compare the effectiveness of single dip and double dip vaccination of Atlantic salmon 
fry. The vaccination experiment was performed at 0.13 g fish when they were started 
commencement of exogenous feeding. If this vaccine performance is effective then it 
will protect fish against Y. ruckeri in their early life stages. 
4.2 MATERIALS AND METHODS 
4.2.1 Fish 
The Atlantic salmon (Salmo salar) alevin used in the experiment weighed approximate-
ly 0.13 g and were provided by Lonnavale hatchery. The fish were acclimated for three 
days to laboratory conditions prior to the experiment. Fish were held in 30 L mesh 
enclosure inside 1000 L holding tanks of a UV-sterilized freshwater recirculating 
system at 11 oC. The commencement of exogenous feeding of all fish obtained from the 
hatchery did not begin until three days after arrival at the laboratory of the university. 
The fish were fed with a commercial crumble feed (Atlantic salmon starter crumbles, 
Skretting, Cambridge, Tasmania). Fish were fed every hour from 9 am to 5 pm until 
visually observed satiation occurred. Water quality, including pH (6.8-7.2), ammonia 
(<0.5 mg L-1), nitrite (<0.05 mg L-1), nitrate (<5 mg L-1) and chlorine (<0.01 mg L-1) 
was checked daily. This experiment was approved by the University of Tasmania Ethics 
Committee (Animal Ethics Number A0012285). 
4.2.2 Preparation of bacterin 
Frozen Y. ruckeri stock, strain UTYR001A, was obtained from the Institute for Marine 
and Antarctic Studies (IMAS), UTAS culture collection, and used to prepare the bacte-
rin and challenge inoculation. A 250 mL brain heart infusion (Oxoid, England) starter 
was inoculated and shaken for 20 h at room temperature (18˚C),  then added to a 10 L 
Nalgene container with 7 L brain heart infusion media and cultured with constant 
aeration for 30 h at room temperature (18˚C). The number of bacterial cells was counted 
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using a Neubauer hemocytometer after inactivating the cells with 10% formalin. The 
formalin was used to inactivate bacteria by adding formalin to 1.2 × 1010 cells/mL to 
achieve a 0.3% final concentration. The number of colony forming units (CFU) per mL 
bacterins used for inactivation was quantified by triplicate plating of the bacteria on LB 
agar (Sigma, USA) plates with a ten-fold dilution series. After the inactivation, the 
vaccine was left for 28 h at room temperature before it was inoculated on LB agar plates 
with 100 µL of inactivated bacteria in triplicate to check the viability. The absence of 
bacterial growth indicated the non-viability after 24 h. The bacterin was stored at 4 oC 
until used for immunisation. 
4.2.3 Vaccination 
Around four hundred fish were used for each treatment. Feed was withheld from fish for 
24 h before they were administered an immunisation via immersion. Vaccinated fish 
were divided into two treatments. One group of fish was vaccinated twice: the first time 
prior to first feed (0.13 g) for the first dip and then at an average weight of 1 g for the 
second dip. Another group was only vaccinated once when the average weight was 1 g. 
During vaccination, the fish were dipped in a 3 L bucket containing a 1:10 dilution of 
the vaccine for 60 s (dipping 50 fish/time) under constant aeration. After vaccination, 
the fish were dipped in freshwater to remove excess vaccine before being returned to 
their respective tanks. The control fish were dipped in freshwater only for 60 s (400 
fish). Feeding was resumed 24 h after booster immunisation with commercial feed. 
4.2.4 Challenge 
At the average weight of 5 g post vaccination, fish from each treatment (n=60) were 
randomly selected and challenged with Y. ruckeri (2.5 × 107 colony forming units 
(CFU)/mL for 1 h) in air saturated 20 L buckets with fresh water at 12oC. Fish were 
challenged and mortality was monitored as described in section 2.2.4. RPS was used to 
evaluate vaccine efficacy at the end of the experiment (30 days after challenge). 
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4.2.5 Sampling 
To demonstrate Y. ruckeri-free status of the population used for this experiment, 10 fish 
(approximately 0.13 g body weight) were lethally anaesthetised with clove oil (0.3 ml in 
1 L water). Each fish was briefly rinsed to remove traces of anaesthetic and homoge-
nised in 1 mL PBS. This homogenate was incubated on TSA plates for 24 h at 18°C. 
The colonies were harvested from TSA plates and analysed using PCR to confirm Y. 
ruckeri-free status. 
An additional 10 fish from each treatment were sampled before first vaccination before 
first feed, before second vaccination when the average weight of fish was 1 g, and 
before challenge when the average weight of fish was 5 g. Due to the small size of the 
fish, blood was only collected when the fish reached the average weight of 5 g. Sampled 
fish were anaesthetised with clove oil (0.3 mL in 1 L of water) prior to blood collection.  
Blood was collected from the caudal vein using a 0.3 mL syringe and a 31 gauge 
needle, and then placed into a 0.6 mL eppendorf tube. Blood samples were allowed to 
clot overnight at 4 oC. Serum was recovered by centrifuging at 500 x g for 10 min at 4 
oC and stored at -20 oC. Gills, intestine and spleen were also collected and placed in a 5 
mL tube of RNA preservation solution (25 mM Sodium Citrate, 10 mM EDTA, 70 g 
ammonium sulphate/100 mL solution, pH 5.2). 10 small fry at first feed and at the 
average weight of 1 g were collected whole from each treatment. These samples were 
refrigerated overnight at 4 oC and then stored at -20 oC. 
4.2.6 Serum ELISA 
ELISA for detection the presence of specific anti-Yersinia antibodies in the blood serum 
was performed as described in section 2.2.6.1. 
4.2.7 Quantitative Real-time PCR Analysis (mRNA expression of RAG-1, IgM, and 
TCR-) 
Immunocompetence was assessed at week 21 using 30 fish ( 5.0 g/fish, 6 
fish/treatment) including unvaccinated fish (control) and two vaccinated groups; includ-
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ing single dip vaccinated fish and double dip vaccinated fish. mRNA expression of 
RAG-1, IgM, and TCR- was determined with different treatments and real-time PCR 
was carried out on spleen samples. 
4.2.7.1 RNA extraction, DNA decontamination and reverse transcription 
Total RNA was extracted from spleen samples. Approximately 2 mg of spleen were cut 
into very small pieces and transferred to a 2 mL round bottom tube with 100 µL of RNA 
extraction buffer [5 M guanidine isothiocyanate, 1% Triton X 100, 50 mM Tris (pH 7)]. 
Then, 100 µL of isopropanol with pink-pellet paint co-precipitate (1:500 Pink: Iso) was 
added and precipitated by centrifugation at 16,000 x g for 10 min at RT. The superna-
tant was discarded and the pellet was incubated for 10 min at 37 oC in 200 µL of 
extraction buffer (4 M Urea, 1% SDS, 0.2 M sodium chloride, 1 mM Sodium citrate) 
supplement with 5 µL of proteinase K (20 mg/mL; Bioline Australia) with occasional 
mixing by vortex to resuspend the pellet. Protein, cellular debris, and detergent were 
then removed by precipitation with the addition of 100µL of 7.5 M ammonium acetate 
centrifugation at 14,000 x g for 10 min 18 oC. Nucleic acids were then precipitated from 
the supernatant by adding one volume of isopropanol with pink-pellet paint co-
precipitate (1:500 Pink:Iso) and centrifugation at 16,000 x g for 10 min at RT. The 
nucleic acid pellet was then washed twice with 75% ethanol and resuspended in 180 µL 
of molecular grade water and 20 µL of 10 X DNAse buffer at 37 oC for 5-10 min. RNA 
was reversely transcribes using a 50 µM of Oligo dT18 primer mix [1 µL of 10 mM 
dNTP, 2 µL of 10 X RT buffer, 0.25 µL of RNAse inhibitor, and 0.25 µL of reverse 
transcriptase (M-MuLV-RT)]. Reactions were performed in a gradient cycler (Master-
cycler Gradient, Eppendorf, Germany) with 20.5 µL reaction volumes containing 500 
ng of total RNA extraction. The reactions were run under the following conditions: 65 
oC for 10 min, 42 oC for 50 min, 70 oC for 15 min and 12 oC indefinitely. 
4.2.7.2 cDNA Template 
Following cDNA generation, the samples were diluted 5 folds with water by adding 80 
µL of molecular grade water to each sample. Five standards were then created by 
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pooling 5 µL of each sample into a single eppendorf tube to create standard 1. The other 
four standards were made by serially diluting in 5-fold dilution with water (i.e. 40 µL 
into 160 µL of water, the highest to the lowest). The negative sample was made by 
pooling 2 µL of RNA of 8 samples of 8 different groups and diluted at the same concen-
tration as the samples for cDNA preparation (in 20 folds). All samples, standards, 
negative sample and non-template control (water) were then transferred to the cDNA 
plate and held at 4 oC for later use. 
4.2.7.6 Real-Time qPCR for Gene Expression Analysis 
A Real-Time qPCR run was performed in duplicate and each Real-Time qPCR master 
mix contained 2.92 µL of water, 0.04 µL of 100 mM F primer, 0.04 µL of 100 mM R 
primer, 5 µL of 2 X My Taq HS Mix (Bioline) and 2 µL of template. These were then 
transferred to a qPCR plate (10 µL/well) of the iQ5 machine by using a multichannel 
pipette. A film seal was applied to the plate and the plate was then short spun at 500 x g 
at 4 oC. A run protocol and the plate setup were selected using real-time software. A 
generic protocol for SensiFast was:  94 oC for 2 min, then 95 oC for 5 sec, 55 oC for 20 
sec and 72 oC for 10 sec for 40 times and then for melting curve 95 oC for 1 min, 55 oC 
for 1 min and 55 oC+1 oC/10 sec for 36 times, until 90 oC. Primers used for real-time 
qPCR are shown in Table 4.1. The amplification efficiency of the standards should be 
85-105% with an R2 higher than 0.98. This real-time qPCR was used to express the 
three different genes of RAG-1, IgM, and TCR-. 
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Table 4.1 Primers used for real-time qPCR 
Gene Name Direction Sequence (5'-3') 
IgM heavy chain 
membrane bound 
form IgM 
IgM Forward TCT GGG TTG CAT TGC CAC TG 
 
Reverse GTA GCT TCC ACT GGT TTG GAC  
Recombination activat-
ing gene-1 
RAG-1 Forward CCT AAC ACC TCT AGG CTT GAC 
 Reverse GCT TCC CTG TTT ACT CGC 
T cell receptor alpha 
chain 
TCR- Forward GCC TGG CTA CAG ATT TCA GC 
 
Reverse 
GGC AAC CTG GCT GTA GTA 
AGC 
Elongation factor 1a EF1a Forward TGATTGTGCTGTGCTTA 
 Reverse AACGCTTCTGGCTGTAGG 
Beta actin β-actin Forward TTGCGGTATCCACGAGAC  
 Reverse TAGAGGGAGCCAGAGAGG  
4.2.8 Statistical analysis 
Survival was analysed using SigmaPlot 11.0, Kaplan-Meier Survival Analysis. Multiple 
comparisons were performed using the Holm-Sidak method including adjustment of the 
P value to avoid type I errors. The results were considered significant when P < 0.05. 
Data input and statistical analysis were achieved using SPSS 22.0 software (SPSS Inc., 
USA). mRNA expression levels were determined by qBase Plus software (Biogazelle, 
Belgium) using the mean expressions of two reference genes – elongation factor 1a 
(EF1a) and b-actin. qBase Plus software was also used to analyse the qPCR data includ-
ing statistical analysis (ANOVA) for significant difference in the mean of expression 
genes of each group. The data were tested using a log-normal distribution in ANOVA. 
4.3 RESULTS 
Survival of unvaccinated fish (the negative control fish) was not significantly different 
from either single dip vaccinated fish or double dip vaccinated fish (P > 0.05). Fish 
mortalities started at day 4 post challenge. The fish vaccinated at 1 g (single dip) had a 
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survival rate of 28.3% and the fish vaccinated before first feed and again at 1 g (double 
dip) had survival rate of 25.0% whereas the negative control fish had survival rate of 
10% by 30 days post challenge (Figure 4.1). 
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Figure 4.1 Effects of vaccination (single dip or double dip vaccination) on survival of 
Atlantic salmon. At the average weight of 5 g post vaccination (21 weeks post-
vaccination), three groups of 90 Atlantic salmon each were challenged by immersion 
with 2.5 × 107 CFU/mL of Y. ruckeri. There were no significant differences in survival 
between any vaccinated groups and the unvaccinated controls (Survival analysis, 
SigmaPlot 11.0, P > 0.05) 
The mortality in vaccinated fish varied from 71.7% to 75.0%, giving the RPS of the 
single dip vaccinated fish and double dip vaccinated fish at 20.4% for 1 Dip and 16.7% 
for 2 Dips (Table 4.2). 
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Table 4.2 Protection of Atlantic salmon following vaccination using single dip 
immersion only or with a single dip immersion follwed by a booster dip immersion 
Treatments No. of fish 
Specific mor-
tality 
Survival (%) 
Mortality 
(%) 
RPS (%) 
2 Dips 60 45 25.0 75.0 16.7 
1 Dip 60 43 28.3 71.7 20.4 
Control 60 54 10.0 90.0 0.0 
No antibody titre was detected in the unvaccinated fish (control), single dip vaccinated 
fish and double dip vaccinated fish. 
The immune status of the two different groups of vaccinated fish at the average weight 
of 5 g was examined by analysing the mRNA expression of IgM, RAG-1 and TCR- by 
real-time PCR. The mean expression levels of IgM in control fish (unvaccinated fish) 
was not significantly different from the other two vaccinated groups, including single 
dip vaccinated fish and double dip vaccinated fish (P > 0.05) (Figure 4.2). However, the 
mRNA expression of RAG-1 and TCR- of all treatment groups including the control 
was below the limit of detection. 
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Figure 4.2 The mRNA expression of IgM at 5 g fish of Atlantic salmon, showing no 
significant difference in expression levels between groups (p>0.05), n = 6, One-way 
ANOVA. 
4.4 DISCUSSION 
The survival of Atlantic salmon in either single dip vaccinated fish or double dip 
vaccinated fish was not significantly different from unvaccinated fish (negative control 
fish) after 30 days of Y. ruckeri challenge (P > 0.05). This may be due to the high 
challenge dose (2.5 × 107 CFU/mL). A previous study showed that the survival of a 
double dip vaccinated group was significantly higher than single dip or bath vaccinated 
groups in immersion vaccination of Y. ruckeri against ERM in rainbow trout (Chettri et 
al., 2015a). However, the results of this study did not show any significant difference 
between the survivals of salmon exposed to a single dip immersion or a single dip with 
a booster (double dip). 
There was no significant difference in expression levels of IgM between the unvaccinat-
ed fish (control) and the other two groups of vaccinated fish. The mRNA expression of 
Chapter 4 
Effects of vaccine application in early life stages of Atlantic salmon 
 
     67 
RAG-1 and TCR- at the time of challenge (5 g) of all treatments exhibited no indica-
tion of expression levels. This may indicate that Atlantic salmon fry that are 1 g or 
smaller are not immunocompetent. This is consistent with previous studies that showed 
Atlantic salmon fry below 1 g had undeveloped immune response as there was no 
indication of TCR-, RAG-1 and IgM (BCR) in the gene expression of 0.15 g fish 
(Gadan et al., 2013). Furthermore, Johnson et al. (1982) suggested that fish less than 1 g 
had a poor response to vaccination because of a poorly developed immune response, 
and only fish of about 2.5 g can achieve long term protection post vaccination. Most 
likely the first vaccination at 0.13 g and the second vaccination at around 1 g were given 
when the fish were not immunocompetent, and this may explain the lack of difference 
in survival rates. 
Serum antibodies against Y. ruckeri were not found in either of the two vaccinated 
groups, or the unvaccinated group at 12 week post immersion vaccination. This may 
indicate that the humoral immunity was not induced by immersion vaccination. A low 
level to undetectable level of serum antibody titres was reported after immersion 
vaccination in rainbow trout, sockeye salmon, carp (Baba et al., 1988; Croy & Amend, 
1977; Liewes et al., 1982; Sakai et al., 1984; Tatner & Horne, 1986). Serum antibody 
levels in rainbow trout immunized by immersion vaccination were induced after 14 to 
30 days post Y. ruckeri challenge (Chettri et al., 2015a). In rainbow trout, Y. ruckeri 
specific antibody levels of vaccinated groups were significantly increased compared to 
unvaccinated group 16 days post Y. ruckeri challenge, but all the fish showed low 
antibody reactivity and an insignificant difference in pre-challenge vaccinated and 
unvaccinated fish (Chettri et al., 2015a). These studies indicated that Y. ruckeri specific 
antibody levels were only induced after Y. ruckeri challenge. This may be a reason why 
no serum antibodies were found in the present study. The production of Y. ruckeri 
specific antibody levels in pre-challenge and post challenge fish should be investigated 
to better understand the role of humoral immunity in immersion vaccination. 
In conclusion, this study has contributed to a better understanding the vaccine perfor-
mance of single dip and double dip immersion vaccination of small hatchery-sized fish. 
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When Atlantic salmon fry weighed around 1 g, the vaccine did not work even as double 
dip. This appeared to be due to the undeveloped immune response in fish this size. The 
lack of measurable serum antibodies against Y. ruckeri indicates the humoral immunity 
was not induced by immersion vaccination. 
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This thesis focused on the effectiveness of different administration methods of immer-
sion immunisation of Atlantic salmon to improve vaccine efficacy against yersiniosis. 
Vaccine against yersiniosis was prepared by three different methods of inactivating Y. 
ruckeri including a novel method using ammonium sulphate that has not been used 
previously for inactivation of bacteria for fish. Ammonium sulphate is the most com-
monly used salt for protein purification and can preserve potential antigens and 
nucleases. Using ammonium sulphate to inactivate Y. ruckeri to produce vaccines may 
be overcome the disadvantage of conventional formalin inactivated bacterin due to the 
lack of cross-linking of proteins. The successful use of ammonium sulphate is described 
in Chapter 2. This bacterin was then combined with hyperosmotic pretreatment in 
immersion vaccination. Chapter 3 demonstrated the improvement in protection of the 
fish from the hyperosmotic pretreatment group compared to the direct immersion group. 
Yersiniosis affects very young fish. A single dip vaccination at first feeding, 0.13 g 
mean weight and double dip immersion vaccination with the first dip applied at the first 
feeding were compared to determine which vaccination regime was more efficient. 
Unfortunately, vaccine efficacy was not achieved for either of the groups (Chapter 4). 
5.1 DIFFERENT WAYS TO MEASURE VACCINE SUCCESS 
Vaccine efficacy is normally evaluated by using survival rate after challenge with live 
pathogen (Munang'andu et al., 2014). Using challenge for testing vaccines has raised 
concerns about animal welfare when large numbers of fish were involved (Stokes et al., 
2011) and the experiments may take long time depending when the protection is meas-
ured post vaccination. Measuring protective antibodies was recommended as a way to 
replace challenge experiments and the use of fish (Stokes et al., 2011). Traditionally, 
antibody levels are used to access vaccine efficacy as their common correlates of 
protection provide by a vaccine (Munang'andu et al., 2014; Plotkin, 2008). In mammals, 
many vaccines are licensed based upon set up antibody titres that act as correlates of 
protection (Munang'andu et al., 2014). However, antibodies associated with protection 
have been observed in fish following immersion vaccination only on a few occasions 
(Nakanishi & Ototake, 1997; Olesen, 1991). In my study, fish serum samples were 
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collected before challenge: at 12 weeks post-vaccination (Chapter 2 and Chapter 3), 
nine weeks and 21 weeks post-vaccination (Chapter 4) to detect antibody levels. Serum 
antibodies (IgM) against Y. ruckeri were not found in any samples of fish serum from 
immersion vaccinated groups in any of the three experiments described in this thesis 
(Chapter 2, Chapter 3 and Chapter 4), even when the vaccinated groups appeared to 
have high protection with survival rates of more than 90% (Chapter 2). These results 
indicate that measuring the IgM antibodies in fish serum for immersion vaccine applica-
tion was not enough to show success of a vaccine and that there was no correlation 
between antibody levels and protection. IgT plays a specialised role in gut mucosal 
immunity, whereas IgM contributes mainly to systemic immune responses (Zhang et al., 
2010). IgT was very weakly expressed after intra-peritoneal vaccination but was highly 
expressed after bath vaccination with Y. ruckeri bacterin (Raida & Buchmann, 2007). 
This suggests that IgT plays a role in mucosal immunity. In my study, an anti-salmonid 
Ig monoclonal antibody was used in ELISA and this antibody only detected IgM in fish 
serum. Therefore, the additional detection of IgT levels in fish gut and gills may show 
the correlation between mucosal antibodies and protection. It would be useful to further 
investigate the measurement of IgT in the gut and gills of vaccinated Atlantic salmon.  
There is a potential to use gene expression post vaccination to identify a potential 
biosignature as a surrogate of protection to predict vaccine success. This method would 
provide important advantages since it would speed up the testing process and reduce the 
need for animal challenges and reduce or eliminate concerns about animal welfare 
(Bhuju et al., 2012; Bridle et al., 2012). Methods of predicting vaccine success have 
been studied in producing vaccines for human, vertebrates and fish (Aranday Cortes et 
al., 2010; Furman et al., 2013; Jiang et al., 2014). A transcriptional biosignature of a 
successful immersion vaccine was identified using differentially regulated genes in the 
gills of Atlantic salmon after immersion vaccination against yersiniosis and before 
bacterial challenge (Bridle et al., 2012). The upregulation of a specific set of genes in 
the spleen of vaccinated Asian seabass (Lates calcarifer) was reported as a biomarker 
for the prediction of successful immune defence against Streptococcus iniae infection 
(Jiang et al., 2014). Chapter 2 investigated the expression of nine genes, out of 17 genes 
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reported previously (Bridle et al., 2012), as a surrogate of protection. The results 
confirmed that upregulation of selected genes may be used to predict the success of a Y. 
ruckeri vaccine. However, six other genes could not be shown useful as predictors of 
vaccine efficacy. This included four genes that were excluded from analysis due to their 
amplification efficiency being outside the acceptable range, while two other genes 
showed opposite results to those reported previously (Bridle et al., 2012) which needs to 
be further investigated to improve our understanding of this potential biosignature in Y. 
ruckeri vaccine. 
5.2 FACTORS AFFECTING CHALLENGE EXPERIMENTS TO 
EVALUATE IMMERSION VACCINATION 
The outcome of a challenge experiment is influenced by the challenge methods used, 
such as i.p. injection challenge or immersion challenge or cohabitation challenge 
(Chettri et al., 2015b; Nordmo & Ramstad, 1997). It was recommended that the control 
treatment should have the lethal rate of at least 60% and effective protection was 
suggested as over 60% (Amend, 1981). When using the same strain, the choice of dose 
for challenge is important in the evaluation of vaccine efficacy. The details of different 
challenge doses and the mortality of the control groups are summarised in Table 5.1. 
Costa et al. (2011) used the challenge dose of 4.3 × 106 CFU m-1 for immersion in Y. 
ruckeri for one hour on Atlantic salmon after 6 weeks post vaccination at 2g fish. The 
results gave more than 80% mortality of the control group. In Chapter 2, lower chal-
lenge dose of 9 × 105 CFU m-1 was used with the same challenge method and at 12 
week post vaccination and the challenge group had 50% mortality that was lower than 
expected. The size of the fish used in Chapter 2 was bigger than the fish used in the 
study of Costa et al. (2011). They were 5 g at vaccination and were challenged 12 weeks 
later. In Chapter 3 and Chapter 4, the mortality rate of the control groups were higher 
than expected. It is recommended that the different challenge doses should be tested 
before the challenge using fish the same size as the experimental fish to make sure that 
the mortality rate in the control group is around 60%. 
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Table 5.1 Challenge doses of Y. ruckeri used for Atlantic salmon by immersion 
challenge for 1 h 
Fish size at 
vaccination 
(g) 
Time for chal-
lenge (weeks post 
vaccination) 
Challenge 
dose 
(CFU/mL) 
Mortality of 
control 
group (%) 
References 
2 6 4.3 × 106 > 80 
Costa et al. 
(2011) 
5 12 9.0 × 105 50 Chapter 2 
2 12 2.5 × 108 78.9 Chapter 3 
0.13 21 2.5 × 107 90 Chapter 4 
The methods to quantify bacteria and the accuracy of the quantification may affect the 
challenge dose. The dose for challenge was confirmed by inoculating bacterin on TSA 
plates and it took 36 hours to know the results (Table 5.1). Before challenge, Y. ruckeri 
numbers were estimated using Neubauer hemocytometer after inactivating the cells with 
formalin. Counting error may occur due to the cells overlapping other cells or missing 
cells if they are not recognised by the person counting the cells. Pipetting errors can 
contribute to challenge dose different than desired (Brecher & Cronkite, 1950). It would 
be useful to reduce counting errors by staining bacteria cells with Trypan Blue to make 
the cell recognition easier (Meyers, 2000) or developing a standard optical density curve 
of Y. ruckeri to estimate accurately the numbers of cells and thus the challenge dose 
(Haig et al., 2011). 
5.3 FUTURE RESEARCH 
As mentioned previously, a novel method of inactivating bacteria using ammonium 
sulphate was successfully used to produce a vaccine (Chapter 2 and Chapter 3). Alt-
hough the survival rate of the ammonium sulphate vaccinated fish was not significantly 
different to the formalin vaccinated fish, the ability of purifying proteins promises 
future improvements of the vaccine. Due to the purification process, ammonium sul-
phate plays important role in developing vaccines in humans (Horwitz et al., 1995; 
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McMaster, 2000a; b). The fish vaccine industry would benefit from research on using 
ammonium sulphate for inactivation. This could involve further experiments with 
different methods of immersion vaccine. For example, single dip and double dip im-
munisation could be compared or combined with double dip with hyperosmotic 
pretreatment of the ammonium sulphate bacterin. A comparison of vaccine storage 
between ammonium sulphate vaccine and formalin vaccine would be useful to under-
stand the ability of preserve antigen of ammonium sulphate. 
Hyperosmotic pretreatment was used for the first time in vaccination against Y. ruckeri 
for Atlantic salmon (Chapter 3). Although RPS was not over 60% (Amend, 1981) most 
likely due to the high challenge dose, the hyperosmotic pretreatment was the only group 
significantly different to the unvaccinated group. A previous study suggested hyperos-
motic pretreatment may cause stress or damage to the fish skin or gills (Nakanishi & 
Ototake, 1997) but my study did not show any evidence of the damage and very few 
studies have shown any the disadvantage of hyperosmotic pretreatment in fish. Further 
experiments with lower challenge dose and the effects on fish gills and stress would 
enhance our understanding of hyperosmotic pretreatment in fish vaccination for Atlantic 
salmon. 
As previously stated, identification of a biosignature as a surrogate measure of protec-
tion would predict vaccine success and reduce concerns about animal welfare in disease 
challenges using fish. The fish vaccine industry would also benefit from further work 
into the transcriptomic response of host immune organs to vaccination if it could 
generate biomarkers that would predict vaccine success for particular species and 
diseases. The expression of six genes, out of the 17 genes identified by Bridle et al. 
(2012), was not measured in this study. These genes can be further investigated in the 
ammonium sulphate vaccinated fish. The measurement of gene expression of these 17 
genes in a commercial vaccine Yersinivac-B or a formalin inactivated vaccine could 
provide clearer evidence of this potential biosignature in prediction vaccine success on 
yersiniosis. 
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The need of early vaccination for early life stages of Atlantic salmon is important. 
However, the sizes when fish have fully developed immunocompetence so they are 
protected after vaccination need to be further investigated. The only study on the 
immunocompetence at different size of salmonids is a study of Johnson et al. (1982) and 
it is on rainbow trout size against Y. ruckeri vaccine and the sizes of other salmonids 
species against Vibrio anguillarum. It would be useful to understand development 
stages of Atlantic salmon by conducting further experiment with different time points of 
immersion vaccine when fish are more than 1 g size or combine immersion with oral 
immunisation in fish smaller than 1 g that had showed some promising results (Ghosh et 
al in prep., Appendix 1). 
5.4 CONCLUSION 
In conclusion, this thesis has increased our knowledge into different methods of immer-
sion immunisation of Atlantic salmon against yersiniosis. The successful use of a novel 
vaccine preparation using ammonium sulphate to inactivate the bacteria was reported 
for the first time for yersiniosis vaccine. Hyperosmotic pretreatment, which to the best 
of my knowledge has not been previously tested in Atlantic salmon, showed improved 
protection against Y. ruckeri. The results of the gene expression study supported the use 
of immune response genes as a biomarker of vaccine success against Y. ruckeri in 
Atlantic salmon. The potential protective nature of antibodies and the correlation with 
vaccine protection still needs to be further investigated including IgT levels to have 
better understanding of fish mucosal immunity. Finally, the study of vaccine perfor-
mance of immersion immunisation of small hatchery-sized fish has contributed to our 
understanding of the effects of administration strategies on vaccination for small fish. 
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Highlights 
· Significant protection from microencapsulated oral vaccine 
· Prolonged protection in absence of adaptive immune response 
· No effect of treatments on asymptomatic infection rates 
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Abstract 
Yersinia ruckeri is a ubiquitous pathogen of finfish capable of causing major mortalities 
within farmed fish stocks. It can be transmitted vertically from parent to progeny as well 
as horizontally in the water column from both clinically infected fish and asymptomatic 
carriers, and therefore capable of infecting fish at early stages of development. Immun-
isation strategies that can protect small fry are therefore critical for the effective 
management of fish health, as is the ability to detect fish carrying covert infection. In 
this study, first-feeding Atlantic salmon fry were immunised either by oral administra-
tion of a microencapsulated Y. ruckeri vaccine formulation, or via immersion in bacterin 
suspension, with and without a booster immersion vaccination at 1 g size. Protection in 
groups receiving only immersion immunisation did not differ significantly from un-
treated controls when challenged with Y. ruckeri at approximately 5 g size, while orally 
immunised fish were significantly better protected than untreated controls (F = 4.38, df 
= 4,10, P = 0.026), with RPS varying between 29.4% (ORAL) and 51% (ORAL+DIP). 
A quantitative real-time PCR assay was used to successfully detect asymptomatically 
infected fish among challenge survivors, indicating more than 50% of surviving fish in 
each group were infected with no significant differences between immunised fish and 
untreated controls. 
Introduction 
Yersinia ruckeri, a Gram-negative member of the family Enterobacteriaceae, is the 
causative agent of Enteric Redmouth disease (ERM) and yersiniosis in salmonids. 
Though first identified from rainbow trout (Oncorhynchus mykiss Walbaum) in the 
Hagerman Valley, USA [1], Y. ruckeri is known to cause disease in several farmed and 
wild species including other salmonids such as Atlantic salmon (Salmo salar L.) [2-5]. It 
is now a ubiquitous pathogen that has been isolated from fish populations around the 
world, as well as from other taxa and environmental samples [6, 7]. 
Y. ruckeri is capable of causing mass mortalities and significantly impacts the global 
salmonid culture industry. It has been reported to cause disease in Atlantic salmon 
stocks, and has been associated with mortalities in the Australian Atlantic salmon 
industry [8-10]. Y. ruckeri outbreaks within the Australian Atlantic salmon industry 
typically result in a less florid form of yersiniosis than in the northern hemisphere, 
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lacking the subcutaneous haemorrhaging in and around the mouth and throat that has 
led to the disease being described as ERM [11, 12]. Yersiniosis in Atlantic salmon 
grown in Australia can be detected through unilateral or bilateral exophthalmia accom-
panied by ocular haemorrhaging, and a distended vent and haemorrhaging at the base of 
pelvic and pectoral fins in advanced stages of infection [11]. 
Early investigations demonstrated the efficacy of immersion vaccination of fish in a 
bacterin as a successful strategy for protecting farmed salmonids against Y. ruckeri, and 
an immersion vaccine consisting of formalin-inactivated whole cells was commercially 
licensed in 1976 in the USA [13]. A similar vaccine, developed by DPIPWE Launces-
ton, Tasmania, has been used extensively to vaccinate fingerlings (body weight 5 g) in 
the Australian salmonid industry. However, outbreaks still occur, and mortality of 
approximately 500,000 fish occurred over a six-month period in 2007 despite stocks 
having been vaccinated [9].  
At present, salmonid fry are initially immunised against Y. ruckeri by immersion 
vaccination at approximately 2 – 5 g size [14, 15], at which point they are still too small 
for intraperitoneal vaccination but large enough to handle without major deleterious 
impacts. Before reaching this size, S. salar fry are not considered to have developed 
sufficient adaptive immunocompetence, and are typically not provided with any form of 
immunoprophylaxis. Given the ubiquity of Y. ruckeri, and its ability to survive in the 
environment without a host [7, 16], the risk of infection in small fish is considerable. 
Immune system components generally develop early in freshwater fish [17], and 
recently, bacterial challenge of rainbow trout larvae and fry has shown that first-feeding 
salmonids may possess a range of innate immune factors that offer protection from 
infection, though the mechanisms involved are not clear [18]. These findings suggest 
that enhancing the immune response in Atlantic salmon fry against pathogenic infection 
may be possible. Recently, onset of Y. ruckeri infection has been observed in fish 
smaller than the minimum vaccinated size in commercial Atlantic salmon populations, 
indicating the importance of developing an effective means of protecting smaller fish 
that is also practicable on a commercial scale.  
Y. ruckeri is capable of establishing and maintaining subclinical infection, resulting in 
asymptomatic carriers. When stressed, these carriers instigate horizontal transfer of the 
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pathogen, subsequently producing clinical infection within a population [19]. Vaccina-
tion using current methods has been unsuccessful in preventing the establishment of 
asymptomatic carriers within stock populations, and clinical expression from pre-
existing subclinical infection has been reported in various salmonid species including 
Tasmanian Atlantic salmon [12, 19, 20]. An immunoprophylaxis strategy capable of 
inhibiting establishment of asymptomatic carriers would therefore prove extremely 
beneficial for salmon health management. 
Mucosal administration of antigens offers the most feasible approach for immunisation 
of small fish. Mucosal immunisation also specifically targets stimulation of mucosal 
immunity in the fish, which arguably provides the first line of defence against most 
pathogens that fish are exposed to [21, 22]. Oral immunoprophylaxis in particular 
represents an ideal strategy for this purpose as it has no fish-size limitations and re-
quires minimal infrastructure and specialized skills for effective implementation. 
However, protection conferred by oral immunisation has proved inconsistent in trials 
[23-27]. Digestive degradation has been implicated as the major cause of this incon-
sistency, as antigenic integrity must be retained until the immunogen reaches the distal 
intestine, which has been identified as an immunologically active part of the gastrointes-
tinal tract involved with uptake of antigens [28-30]. Some studies in different teleost 
species have also reported observations of oral tolerance, a phenomenon characterized 
by a decrease in immune response linked to the extended administration of orally 
delivered antigens in various fish species including salmonids [31-33], suggesting 
interrupted administration regimes to address the issue. 
Biopolymeric microencapsulation of orally administered antigens has demonstrated 
some success in protecting fish from pathogens. Besides effectively protecting immu-
nogenic material from digestive degradation, microencapsulation increases its 
bioavailability due to particulate dispersion and the potential to affect controlled release 
of the antigenic substance. Several biopolymers used in antigen microencapsulation are 
also known to have intrinsic adjuvant properties, making their use advantageous in 
immunoprophylaxis [34, 35]. 
The aim of this study was to assess comparative protection afforded to first feeding 
Atlantic salmon fry against bacterial challenge with pathogenic Y. ruckeri when immun-
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ised by oral administration of a microencapsulated Y. ruckeri vaccine or by immersion 
in concentrated bacterin. 
Materials and Methods  
Ethics statement 
All procedures on fish were performed in accordance with the Australian Code of 
Practice for the Care and Use of Animals for Scientific Purposes and approved animal 
handling guidelines (University of Tasmania Animal Ethics Committee approval Ref: 
A12285). 
Fish source, maintenance and experimental design 
Atlantic salmon (Salmo salar L.) were used throughout this study. For in vivo uptake 
investigation, 20 fry with a mean weight of 1 g were obtained from a commercial 
Tasmanian hatchery and held in a 20 L mesh enclosure within a 1000 L tank supplied 
by recirculating freshwater at 11°C. For immunisation studies, pathogen-free alevin 
were obtained from a commercial Tasmanian hatchery prior to commencement of 
exogenous feeding. They were divided into two groups corresponding to the two routes 
of immunisation – oral and immersion – and acclimated for three weeks in a UV-
sterilised freshwater recirculating system at 11°C. Post-acclimation, fish at a mean 
weight of 0.32 g were transferred to 200 L tanks, supplied by UV-sterilized recirculat-
ing freshwater at 11°C. Other water quality parameters including pH (7.2–7.6), 
ammonia (<0.25 mg L−1), nitrite (<0.25 mg L−1), nitrate (<0.5 mg L−1) were monitored 
daily. Exogenous feeding commenced 24 h after transfer, and fish were then fed daily to 
satiation with a commercial crumble feed (Skretting, Cambridge, Tasmania). Tanks 
were randomly allocated to specific treatment groups, comprising three replicate tanks 
containing 35 fish each (Table 1). Fish were starved for 24 h seven days after initial 
feeding, following which experimental treatment administration was commenced. 
Yersinia ruckeri culture 
All Yersinia ruckeri cultures were grown in tryptone soy media (Oxoid, Basingstoke 
UK), either as broth (TSB) or agar (TSA), using aseptic techniques. For im-
munoprophylactic preparation, 15 mL TSB was inoculated with frozen Y. ruckeri stock 
(strain UTYR001) and incubated at 18°C overnight to obtain a starter culture. Starter 
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culture was used to inoculate 50 mL TSB (1:100 v/v), which was incubated at 18°C 
overnight, and in turn used to inoculate 5 L TSB (1:100 v/v), and incubated at 18°C for 
24 h with constant aeration. For bacterial challenge, the same procedure was followed to 
achieve a final culture volume of 7 L. 
Preparation of oral vaccine 
Cultured Y. ruckeri cells were inactivated by the addition of neutral-buffered formalin at 
0.3% of total volume and subjecting the culture to constant agitation over 24 h. TSA 
plates were inoculated with 100 µL of inactivated bacteria in triplicate, and incubated at 
18°C for 24 h to confirm bacterial inactivation. Inactivated bacteria were concentrated 
by centrifuging at 8000xg for 30 min and washed twice in PBS. Concentrated cells were 
combined with distilled water (4:1 v/v) and resuspended by 60 s vigorous agitation. 
Cells in suspension were disrupted by four cycles of ultrasonication (60 s on / 30 s off) 
while held on ice. 
Y. ruckeri lysate was microencapsulated using methods adapted from Zheng et al. [36]. 
Briefly, lysate was combined with a 4% (w/w) aqueous solution of sodium alginate salt 
(medium viscosity; Sigma-Aldrich) in 1:3 ratio (v/v) and stirred for 10 min to produce a 
3% final alginate concentration. This was gradually introduced into the oil phase 
(octane containing 7.5% v/v Span-80; Sigma-Aldrich) in a 1:2 ratio (v/v) and emulsified 
by stirring at approximately 8000 rpm with the addition of Tween-80 (3.3% v/v; Sigma-
Aldrich). Microcapsules were calcium-crosslinked over 45 min, hardened in isopropyl 
alcohol for 25 min and recovered by centrifuging the mixture at 2000xg for 10 min. 
Recovered microcapsules were washed twice in distilled water and then lyophilised. 
Commercial feed was lyophilised until reduced in weight by 50% and crushed to a fine 
powder. Lyophilized microcapsules were mixed with powdered feed (1:100 w/w) until a 
uniform mixture was achieved. Distilled water was added to the mixture (50% w/w) and 
combined to form a dry paste, which was extruded and dried at 18°C. Dried treated feed 
was crushed coarsely and sieve-separated to obtain particles commensurate to fish size 
over the duration of treatment administration. 
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Fluorescent labelling of vaccine microcapsules 
All protocols involving fluorescein isothiocyanate (FITC; Sigma-Aldrich, St. Louis 
MO, USA) were performed under protection from light exposure. Y. ruckeri microcap-
sules were labelled for validation of uptake after oral administration by affecting the 
modifications to the oral vaccine manufacture process. 
Briefly, sonicated Y. ruckeri lysate was fluorescently labelled by combining with FITC 
solution (2.5% w/w in 1M phosphate-buffered saline; PBS) at a 2:1 ratio (v/v) and 
incubated at 30°C for 4 h. FITC-labelled cell lysate was dialysed against 0.01M PBS 
over 24 h to remove superfluous FITC. To produce FITC-labelled alginate, FITC 
solution (in 1M PBS) was combined (0.15% v/v) with 4% (w/w) aqueous alginate 
solution previously adjusted to pH 9, and incubated for 1.5 h at 40°C with continuous 
stirring. FITC-labelled alginate solution was dialysed against distilled water for 24 h at 
4°C to remove any uncoupled FITC. FITC-labelled lysate was combined with FITC-
labelled alginate solution in 1:3 ratio (v/v) and stirred for 10 min to produce a 3% final 
alginate concentration, which was used as the aqueous phase for manufacture of FITC-
labelled microcapsules, subsequently combined combine with feed as described. 
Preparation of immersion vaccine 
Vaccine for immersion immunisation was prepared using a 24 h culture of Y. ruckeri 
cells in TSB, grown with constant aeration at 18˚C. Culture was inactivated by the 
addition of neutral-buffered formalin at 0.3% of total volume followed by constant 
agitation over 24 h, and then stored at 4°C until used for immunisation. TSA plates were 
inoculated with 100 µL of inactivated bacteria in triplicate, and incubated at 18°C for 24 
h to confirm bacterial inactivation. Inactivated culture was diluted 1:10 for immunisa-
tion, to achieve a final suspension of approximately 1.29 x 109 cells mL-1.  
Immunisation 
Fish were divided into five treatment groups comprising an untreated control group 
(CONTROL), fish receiving orally administered vaccine (ORAL), fish receiving 
vaccine through oral administration as well as a booster immersion-vaccination 
(ORAL+DIP), fish immersion-immunised prior to commencement of exogenous 
feeding (1DIP), and fish that were immersion-immunised prior to exogenous feeding as 
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well as receiving a booster immersion-immunisation later (2DIP).  Treatments for 
groups are summarised in Table 1. 
Oral immunisation 
Prior to commencement of oral immunisation treatments, all fish were fed untreated 
commercial feed ad libitum for 14 days after treatment-group allocation, during which 
time palatability of treated feed was assessed using 10 fish maintained in an isolated 
system. Vaccine-treated feed was administered according to a staggered regime to 
minimise potential development of oral tolerance (see Rombout et al. [37]). The ORAL 
and ORAL+DIP groups received treated feed, prepared as described, for seven consecu-
tive days, followed by seven days of untreated feed. This 14-day regime was repeated 
thrice, achieving 21 days of treated feed administration in total. Following completion 
of the oral treatment regime, all fish were returned to untreated commercial feed until 
bacterial challenge. Fish in the CONTROL group were maintained on untreated com-
mercial feed throughout, until bacterial challenge. 
When at a minimum weight of 1 g (Mean weight 1.78 g), feed was withheld from fish in 
the ORAL+DIP group for 24 h, following which they were administered a booster 
immunisation via immersion. Fish from each replicate tank were immersed in 5 L of 
previously prepared vaccine suspension for 60 s under constant aeration, followed by 
transfer to running dechlorinated freshwater for 60 s before being returned to their 
respective tanks. Feeding with untreated commercial feed was resumed 24 h after 
booster immunisation. 
Immersion immunisation 
Prior to commencement of exogenous feeding, fish allocated for immersion immunisa-
tion (Mean weight 0.26 g) were immersion-vaccinated in 5 L of previously prepared 
vaccine suspension for 60 s under constant aeration, followed by transfer to running 
dechlorinated freshwater for 60 s before being returned to their respective tanks. When 
at a minimum weight of 1 g (Mean weight 1.2 g), feed was withheld from fish in the 
2DIP group for 24 h, following which they were administered a booster immunisation 
via immersion as before. Feeding with untreated commercial feed was resumed 24 h 
after booster immunisation. 
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Sampling 
Establishment of Y. ruckeri-free status 
Immediately after transfer to acclimation tanks, 10 randomly selected individuals 
(approximately 0.32 g body weight) were lethally anaesthetised (5 ml L-1 Aqui-S; NZ, 
Lower Hutt, New Zealand). Each fish was rinsed briefly to remove traces of anaesthetic, 
homogenised in 1 mL PBS, and the homogenate was incubated for 24 h at 18°C on TSA 
plates for analysis of colonies using PCR to confirm Y. ruckeri-free status. 
Oral uptake validation 
To determine uptake of oral vaccine, 15 fry randomly selected prior to group allocation 
were transferred to an isolated system with identical environmental parameters and 
maintained on untreated commercial feed until approximately 1 g (Mean weight 1.3 g). 
Feed combined with FITC-labelled Y. ruckeri microcapsules was administered ad 
libitum twice over a 24 h period. Fry were lethally anaesthetised 48 h after final feed. 
Maintaining protection from light exposure, spleen, liver and kidney were removed and 
fixed in Davidson’s (freshwater) fixative over 24 h, and then prepared for histology by 
ethanol-series dehydration, paraffin infiltration and embedding in paraffin blocks. The 
blocks were sectioned at 5 µm using a microtome (Microm HM340, Germany) and 
mounted on glass slides, all according to standard histological procedures. Prepared 
sections were observed under a compound microscope equipped with fluorescent 
illumination (Olympus BH2, Japan) and uptake of FITC-labelled microcapsules and 
contents was evaluated visually. 
Immune response and challenge mortality 
Immediately prior to commencement of bacterial challenge, six fish (approximately 5.0 
g body weight) were randomly selected from each group and lethally anaesthetised. 
Spleens were fixed in 1.5 mL RNAlater over 24 h at 18°C, and then stored at -20°C 
until analysed for assessment of immune gene expression. Immediately prior to chal-
lenge, 10 fish weighing approximately 5 g each were anaesthetised (0.3 ml L-1 Aqui-S) 
and blood was collected from the caudal vein using a 0.3 mL syringe and transferred to 
microcentrifuge tubes. Blood was allowed to clot overnight at 4°C and serum was 
recovered for antibody titre analysis by centrifuging at 4°C for 10 min at 500 xg. 
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Throughout the challenge period, reisolation of Y. ruckeri was attempted from 20% of 
daily mortalities per tank by inoculating TSA plates with kidney samples excised from 
mortalities. Colonies were identified using Y. ruckeri-specific 16S ribosomal gene 
primers through PCR to confirm Y. ruckeri as the cause of mortality. 
Y. ruckeri challenge 
Six randomly selected fish from each tank were transferred to a pathogen-free system 
with identical environmental conditions and water supply (n=18 per group), to be 
maintained as challenge controls. Nine weeks (at 11°C) after administration of booster 
immunisation, fish from all three replicate tanks within each treatment group were 
challenged by a 60 min immersion in 15 L freshwater saturated with air and containing 
pathogenic Y. ruckeri (75 mL culture) at a final concentration of 2.5 x 107 colony 
forming units (CFU) mL-1. Initially estimated by optical enumeration, the dose was 
confirmed as per previously published methods [38] using TSA plates incubated at 
18°C for 36 h. Following immersion, fish were returned to their respective tanks. Tanks 
were monitored for mortalities, which were sampled as described, for 21 days post-
challenge. Cumulative percent mortality (CPM) from each treatment was used to 
calculate the relative percent mortality (RPS) as RPS = (1 – (mean treatment group 
CPM/control group CPM)) x 100. Challenge control fish were mock-challenged by 
similar immersion in 15 L freshwater containing 75 mL sterile TSB before being 
returned to their respective enclosures. 
Assessment of Y. ruckeri - specific antibody response 
Adaptive immune response to vaccination by oral and immersion routes was evaluated 
by measuring Y. ruckeri – specific antibody titres in serum of treated fish. This was 
achieved through an enzyme-linked immunosorbent assay utilising Y. ruckeri lipopoly-
saccharide antigen. 
Production of Y. ruckeri lipopolysaccharide (LPS) antigen 
Formalin-inactivated Y. ruckeri cells were concentrated by centrifuging at 4°C for 30 
min at 8000 xg, resuspended in 2.2 mL of distilled water and combined with 0.4 mL 
100 mM Tris-HCL (pH 8.0), 0.4 mL 0.5 M magnesium chloride and 1.0 mL of 8% 
Triton X-100. The mixture was heated in boiling water for 10 min, cooled and concen-
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trated by centrifuging for 15 min at 15000 xg. The pellet was washed in 10 mM Tris-
HCl (pH 8) / 10 mM magnesium chloride, followed by resuspension in 4 mL resuspen-
sion buffer (equal volumes of distilled water, 0.2 M EDTA, 8% Triton X100 and 2 M 
sodium chloride). The suspension was incubated at 37°C for 1 h, centrifuged for 15 min 
at 15000 xg, and the supernatant transferred to a fresh tube containing 0.6 mL 1 M 
magnesium chloride and mixed thoroughly. To this mixture, 1 mL 100% ethanol was 
added drop-wise, followed by incubation at 37°C for 1 h before centrifuging at 20°C for 
5 min at 18514 xg. The transparent precipitate obtained was washed in 10 mM Tris-HCl 
(pH 8) / 10 mM magnesium chloride and used as antigen in the enzyme-linked im-
munosorbent assay. 
Enzyme-linked immunosorbent assay (ELISA) 
A monoclonal anti-salmonid Ig (H chain) antibody (CLF004HP; Cedarlane Laborato-
ries, Canada) was used in an indirect ELISA to determine Y. ruckeri – specific antibody 
titres in serum. LPS antigen of Y. ruckeri was diluted in coating buffer to 10 µg mL-1 
and used to coat wells in a 96-well flat bottomed plate (Asahi Glass Company, Japan) 
by adding 100 µL well-1 and incubating overnight at 4°C. Excess coating solution was 
removed by washing three times in a low-salt wash buffer. To reduce non-specific 
binding, wells were incubated for 2 h with 250 µL 3% (w/v) non-fat dry milk, followed 
by three washes using a low-salt wash buffer. 
Serum was diluted 1:100 in PBS and 100 µL well-1 added in duplicate. Pooled hy-
perimmune serum obtained from IP-immunised fish from a previous study was diluted 
from 1:100 to 1:3200 in a series of doubling dilutions in PBS to establish a standard 
curve, and added at 100 µL well-1. Plates were sealed and incubated for 2h at 18°C with 
gentle shaking, followed by five washes with a high salt wash buffer, which included a 
5 min incubation at room temperature in the final wash step. Reconstituted horseradish 
peroxidase (HRPO) conjugated – monoclonal anti-salmon Ig (CLF004HP; Cedarlane 
Laboratories) was diluted 1:500, and 100 µL added to each well prior to incubation at 
18°C for 1 h. Following incubation, wells were washed five times with a high salt wash 
buffer, which included a 5 min incubation at room temperature in the final wash step. 
Chromogen (G7431 TMB One Solution, Promega, USA) was added (100 µL well-1) and 
plates were incubated at room temperature for 10 min before addition of a stop solution 
Appendix 
 
     105 
(1 M sulphuric acid; 100 µL well-1). The plate was read at 450 nm following 10 s of 
shaking (Tecan Thermo-Spectra Rainbow, Austria). Standards were assigned an arbi-
trary absorbance unit (AU) value, increasing serially two-fold from 3.125 AU for 
1:3200 dilutions to 100 AU for 1:100 dilutions. A standard curve was generated and 
used to determine relative absorbance in serum from experimental samples. 
Assessment of immune-related gene expression 
Differential expression of Recombination activation gene 1 (RAG-1), membrane-bound 
Immunoglobulin-M (IgMMB) and T cell receptor α (TCR-α) in spleens of fish from each 
group, sampled pre-challenge, was analysed by real-time quantitative PCR to assess 
differences in immune response elicited by the different immunisation treatments. 
RNA extraction, DNA decontamination and cDNA synthesis 
Pieces of spleen (approximately 2 mg) were rinsed in water to remove excess RNAlater. 
Samples were then incubated at 4°C with 100 µL RNA Extraction buffer [5 M guani-
dine isothiocyanate, 1% Triton X 100, 50 mM Tris (pH 7)], mixed with  100 µL 
isopropanol and precipitated by centrifugation at 16000xg for 10 min at RT. Superna-
tant was discarded, and the pellet was incubated for 10 min at 37°C in 195 µL Urea 
extraction buffer (4 M Urea, 0.2 M sodium chloride, 1 mM tri-sodium citrate, 1% SDS) 
supplemented with 5 µL Proteinase K (20 mg mL-1; Bioline Australia) with occasional 
agitation until resuspension of the pellet was achieved. Protein, cellular debris, and 
detergent were removed by centrifugation in 7.5 M ammonium acetate at 14000×g for 
10 min at 18°C, and nucleic acids were recovered by isopropanol precipitation of the 
supernatant at 16000xg for 10 min at room temperature and washed twice with ethanol. 
The RNA pellet was eluted over 10 min at 37°C in 180 µL molecular grade water 
supplemented with 20 µL 10X DNAse buffer. The suspension was combined with 3 µL 
of DNAse (Baseline-ZERO™, DNAse 1000 U@1U µL-1), incubated for 60 min at 37°C 
and transferred to ice for 5 min. Digested DNA was precipitated by centrifugation in 7.5 
M ammonium acetate at 14000×g for 10 min at 18°C. RNA was recovered by isopropa-
nol precipitation of supernatant at 16000xg for 10 min at RT. The pellet was washed 
twice in ethanol and eluted in 20 µL water containing 20 mM dithiothreitol (DTT; 
Sigma-Aldrich). Eluted RNA concentration was fluorometrically quantified (Qubit 
RNA BR assay, Invitrogen), and an aliquot run on a 1% agarose -Tris-borate EDTA 
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(TBE) gel containing RedSafe™ Nucleic Acid Staining Solution (Intron; 6x10-5 % v/v) 
to verify RNA integrity. 
A negative control was produced by pooling 2 µL of each extracted RNA sample across 
all the treatment groups, and then diluting in molecular grade water (1:4). A portion of 
each extracted RNA sample (≈500 ng) was reverse transcribed using a 50 µM Oligo 
dT18 primer mix [1 µL 10 mM dNTP, 2 µL 10X RT buffer, 0.25 µL RNAse inhibitor, 
and 0.25 µL reverse transcriptase (M-MuLV-RT)] in molecular grade water to a final 
volume of 20.5 µL. Reverse-transcribed samples were diluted in water (1:4), and 5 µL 
of each diluted sample was pooled and serially diluted five-fold to create five standards. 
Asymptomatic carrier analysis 
Following termination of challenge, challenge survivors were transferred from chal-
lenge tanks to one of three enclosures corresponding to each treatment group in a 
system free from Y. ruckeri. Feeding with commercial feed was resumed 24 h after 
transfer, and enclosures were observed for mortalities over four weeks. At the end of 
this period, all surviving fish from each group were lethally anaesthetised. Spleens were 
excised, fixed in 1.5 mL RNA preservation solution (4M Ammonium sulfate, 25 mM 
Sodium citrate, 10mM EDTA, pH 5.2) over 24 h at 18°C, and then stored at -20°C. 
Whole spleen from each fish was analysed for Y. ruckeri load using real-time qPCR 
with Y. ruckeri-specific 16S ribosomal gene primers to determine asymptomatic carrier 
status of fish in each group. Briefly, spleen was rinsed in water to remove excess 
fixative and then cut into pieces (approximately 2 mm x 2 mm) to facilitate efficient 
lysis. Samples were incubated at 37°C for 30 min in 495 µL Urea extraction buffer 
supplemented with 5 µL Proteinase K to lyse cells. The resulting suspension was cooled 
on ice for 5 min and protein, cellular debris, and detergent were removed by centrifuga-
tion in 7.5 M ammonium acetate at 14000×g for 3 min at 18°C. Nucleic acids were 
recovered by isopropanol precipitation at 14000xg for 10 min at RT. The nucleic acid 
pellet was washed twice with ethanol and eluted in 100 µL water containing 10 µM 
TRIS-HCL and 0.05% TritonX (v/v). 
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Real-time quantitative PCR (qPCR) analysis 
All real-time qPCR analyses were conducted on a CFX Connect Real-Time PCR 
detection system (Bio-Rad) with efficiency and stringency of standard curves held to 
between 85-110% and 0.98-1.00.  
Immune gene expression analysis 
Primers and probe used for gene-expression analysis are presented in Table 2. Each 
PCR reaction consisted of 5 µL 2X MyTaq HS Mix (Bioline) containing 0.5X SYBR 
Green (Invitrogen), forward and reverse primers (400 nM each), and 2 µL DNA tem-
plate in molecular grade water to a final volume of 10 µL. Cycling conditions consisted 
of an initial activation of DNA polymerase at 94°C for 2 min, followed by 40 cycles of 
5 s at 95°C, 20 s at 55°C and 10 s at 72°C. A melt curve was initiated at 95°C for 60 s, 
followed by 60 s at 55°C. The melt curve was generated by increasing the temperature 
in 36 increments of 1°C every 10 s to a maximum of 90°C. mRNA expression levels 
were standardized against mean expression levels of two reference genes [elongation 
factor 1α (EF1α) and β-actin] were analysed by ANOVA using the qBase Plus software 
(Biogazelle, Belgium). 
Detection of asymptomatic Y. ruckeri infection 
Primers and probe used for detection of Y. ruckeri are presented in Table 2. Each PCR 
reaction consisted of 5 µL 2X MyTaq HS Mix (Bioline), forward and reverse primers 
(400 nM each), Y. ruckeri 16S ribosomal gene-specific Taqman probe (100 nM) and 2 
µL DNA template in molecular grade water to a final volume of 10 µL. Cycling condi-
tions consisted of an initial activation of DNA polymerase at 95°C for 3 min, followed 
by 40 cycles of 5 s at 95°C and 30 s at 60°C. Assay results were quantified by analysis 
of raw fluorescent unit (rfu) data using the CM3 mechanistic model included in the 
qPCR package (v. 1.4-0) for RStudio statistical computing software [39]. 
Statistical analysis 
Analysis of realtime qPCR results from gene expression assays was performed using the 
qBase Plus software. All other statistical analyses were performed in R (statistical 
computing software) [39], with results considered statistically different when P ≤ 0.05. 
Analysis of realtime qPCR results from the Y. ruckeri detection assay was performed 
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using the CM3 model in the ‘qpcR’ package [40] for R. Analysis of Variance 
(ANOVA), performed through the ‘ez’ package [41] for R, was used to compare 
differences between treatments as appropriate, using Levene’s Test to verify homosce-
dasticity. Tukey’s HSD post-hoc test was used to determine significantly different 
treatments. Survival curve analysis was performed using the Log-rank test in the 
‘survival’ package for R [42], with a Bonferroni correction set to allow for multiple 
pairwise curve comparisons. Difference in percentage of asymptomatic carriers was 
tested for significance using Chi-square analysis. 
Results 
In vivo microcapsule uptake and content distribution 
Distinct areas of fluorescence were observed in kidney, liver and spleen from fish in the 
ORAL and ORAL+DIP groups, indicating translocation of the FITC-labelled to immu-
nologically important organs, and retention over 48 h post-administration (Fig. 1). No 
such fluorescence was observed in organs of fish from the CONTROL group. 
Y. ruckeri challenge 
Both ORAL and ORAL+DIP groups demonstrated moderate protection against Y. 
ruckeri challenge compared with untreated controls, with RPS values of 29.4% and 
51% respectively. Protection was lower in the 1DIP (RPS = 20.4%) and 2DIP (RPS = 
16.7%) groups, which were immunised only via immersion. There was a significant 
difference in CPM observed between the groups, with CPM in both the ORAL and 
ORAL+DIP groups being significantly lower than untreated controls (F = 4.38, df = 
4,10, P = 0.026). CPM in the 1DIP and 2DIP groups was not significantly from each 
other or from the CONTROL group. In contrast, survival curve analysis indicated a 
significant difference in disease kinetics between the untreated controls and ORAL, 
ORAL+DIP and 1DIP groups (Χ2 = 26.06, P < 0.001). Pairwise comparisons indicated 
that while the ORAL+DIP group was significantly different from the two immersion-
vaccinated groups, the ORAL group was not (Fig. 2). No mortalities were observed in 
any of the challenge control (mock infected) fish.  
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Immune response assessment 
Antibody titres were not significantly different between treatment groups and controls, 
and no significant differences in mRNA expression of RAG-1, IgMMB or TCR-α were 
observed between any of the groups (data not shown). 
Asymptomatic carrier status 
None of the survivors exhibited any abnormal behaviour or gross physiological signs 
characteristic of yersiniosis when sampled. All groups included some asymptomatic 
carriers, based on analysis of survivor spleens for systemic presence of Y. ruckeri (Table 
3). Percentage of asymptomatic carriers detected in each group ranged from 51.43% 
(ORAL+DIP) to 81.82% (1DIP), though there were no significant differences between 
groups.  
Discussion 
This study examined the possibility of effective immunoprophylaxis in first-feeding S. 
salar fry against the effects of a bacterial pathogen, Y. ruckeri. Two routes of mucosal 
immunisation, oral administration and immersion, were investigated with and without 
an additional booster immersion-immunisation.  The oral immunoprophylactic treat-
ment administered to first-feeding S. salar fry in this study clearly conferred protection 
against mortality due to Y. ruckeri infection, as evidenced by significantly lower CPM 
levels than untreated controls. In comparison, mortality in the 1DIP and 2DIP groups 
did not differ significantly from the CONTROL group. The lack of significant protec-
tion in the immersion-immunised groups appears to corroborate previous findings from 
attempts to protect fish in early stages of development from yersiniosis using an immer-
sion-based approach [43], though the mechanisms responsible for protection in orally 
immunised groups were not evident in this study.  
Prior research has indicated that S. salar do not attain complete adaptive immune 
maturity while small fry, rationalising the lack of effort directed at immunoprophylaxis 
of fish at this stage of development [43]. Challenge survival in the ORAL and 
ORAL+DIP groups indicated a long-lasting protective effect, evident at 11°C up to 100 
days after cessation of oral treatment and 63 days after booster immunisation, that was 
conceivably adaptive in nature. However, no significant differences were observed 
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between immunised groups and control fish in antibody titres and regulation of IgM, 
RAG-1 and TCR-α mRNA transcripts, which were assayed to detect potential induction 
of a specific immune response [44-46]. This is in agreement with conclusions drawn by 
Zapata et al. [47] regarding the delay in development of functional immunocompetence 
in contrast to ontogeny of the immune system [48]. However, the lack of adaptive 
immunity apparently exhibited by the ELISA results and gene expression does not 
explain the outcomes achieved here using oral administration strategies. 
The additional administration of a booster immersion-immunisation also appears to 
have contributed positively to immunoprophylactic performance of the orally adminis-
tered antigen, demonstrated by the results of survival curve analysis indicating a 
significant difference between the ORAL and ORAL+DIP treatment groups. In contrast, 
the disease kinetics exhibited by the 2DIP group were not significantly different the 
1DIP group, suggesting that protective efficacy of the booster vaccination is not simply 
an additive effect, but instead dependent on the immune status already achieved in fry at 
the time of administration. The difference in performance of the two booster immunised 
treatment groups, ORAL+DIP and 2DIP, may also reflect a difference in immune 
response resulting from the different routes of immunisation. Previous research on 
immunisation of teleost fry found that lower protection was achieved through early 
primary vaccination by immersion followed by a booster compared to primary vaccina-
tion at a later stage without a booster [49]. The investigators inferred that this was 
caused by immunological tolerance produced by primary immersion immunisation 
attempted while fry were still incapable of generating a specific immune response. They 
also indicated that low immune response in fry receiving primary immunisation at an 
early stage of development may have been a result of agglutination by congenitally 
derived non-specific antibodies. In the current study, similar mechanisms may have 
been responsible for the low survival observed in the 1DIP and 2DIP groups.  
The increased survival in orally immunised groups in this study cannot be explained by 
a typical adaptive immune response. Conventional understanding of the innate immune 
response, in teleosts and in other vertebrates, has involved a naïve response to discrete 
pathogenic encounters, facilitated by germ-line encoded recognition of conserved 
molecular patterns. However, recent studies in mammalian models have demonstrated 
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adaptive responses in cells of the innate immune system [50], specifically in or non-
specific cytotoxic cells (NCC) [51-53]. The existence of similar processes in teleosts 
was recently validated using Rag-1 deficient mutant zebrafish (Danio rerio), which 
exhibited adaptive immune responses to challenge with a bacterial pathogen after an 
initial low dose exposure to it in spite of TCR and Ig transcript expression being absent 
[54]. However, the underlying mechanisms have not been explained in either the 
mammalian or the teleost model. Immunostimulation of NCCs using orally adminis-
tered adjuvants, including naturally occurring biopolymers has been successfully 
demonstrated in murine models [55, 56]. In light of these findings, while not specifical-
ly assessed in this study, it is possible the protection observed in the ORAL and 
ORAL+DIP groups is due to NCC activity. This lack of understanding regarding the 
specific mechanisms responsible for the protection observed here represents an im-
portant area for further investigation. 
The difference in performance of the two booster immunised treatment groups, 
ORAL+DIP and 2DIP, may reflect a difference in immune response resulting from the 
different routes of immunisation. A similar phenomenon was observed in a previous 
study, where Channel catfish (Ictalurus punctatus) fry receiving a secondary (booster) 
immersion immunisation produced a considerably weaker immune response than those 
receiving a primary immunisation at the same size and age [49]. The investigators 
inferred that this was caused by immunological tolerance produced by primary immer-
sion immunisation being attempted in the booster-immunised fry while still 
immunologically incapable of generating a specific immune response. They also 
indicated that low immune response in fry receiving primary immunisation at an early 
stage of development may have been a result of agglutination by congenitally derived 
non-specific antibodies. In the current study, similar mechanisms may have been 
responsible for the low survival observed in the 1DIP and 2DIP groups.  
Assessment of orally-administered antigen uptake in this study provided clear evidence 
of oral administration being a viable strategy for delivery of immunoprophylactics to 
teleosts. Confirmation of particulate uptake in the gut was confirmed, corroborating 
previous research on particulate uptake in the distal intestine [57]. Studies investigating 
the premise of oral antigen uptake in the teleost gut have shown evidence of antigen 
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translocation following enteric administration to immunologically important organs [57-
59]. The results in this study support these earlier findings, and clearly validate the 
premise of oral immunoprophylaxis for teleosts. However, while the microencapsulat-
ing material used – alginate – is known to be a potential immunostimulant, its possible 
contribution to the results observed cannot be assessed independently from effects of 
the Y. ruckeri vaccine in this study. In light of previous research successfully demon-
strating the immunostimulatory effects of alginate in a variety of species [60-63], and 
particularly at early developmental stages [64], clarifying the effects of the alginate 
microencapsulant used in this study independently may be of value to future oral 
immunoprophylaxis strategies for teleost fry. 
Asymptomatic infection of salmonids with Y. ruckeri has previously been detected in 
association with intestinal mucosa [20, 65]. A number of studies have demonstrated that 
teleost mucosal surfaces are capable of producing localized adaptive immune responses 
to antigens [22, 37, 66], and the possibility of inhibiting establishment of asymptomatic 
Y. ruckeri infection through vaccine-mediated adaptive mucosal responses was assessed 
by comparing the proportion of carriers within survivor from each group in this study. 
Increased protection did not translate to increased inhibition of asymptomatic infection, 
with qPCR-based detection showing no significant differences between surviving 
populations of any treatment group. This appears to further suggest that the increased 
protection observed in orally immunised groups was not achieved through conventional 
adaptive immune responses. 
In conclusion, protection of S. salar fry against effects of bacterial infection could be 
achieved via oral immunoprophylaxis more effectively than through immersion immun-
isation in this study. A better understanding of potential specificity of the innate 
immune system in teleosts is, however, critical to further development of disease 
management strategies for fish in early stages of development. A clearer understanding 
of the role played by biopolymer microencapsulants as used here would also contribute 
to further optimisation of such oral immunoprophylaxis strategies. However, the 
potential for developing orally administered immunoprophylaxis as a disease manage-
ment strategy for S. salar fry is clearly demonstrated here. 
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Tables and Figures 
Table 1: Viability of C6-6 in treatments and total approximate dose per fish prior to 
bacterial challenge 
Group 
Label 
Immunisation Fish/Tank 
ORAL 3 x (7 d treated feed / 7 d untreated feed) 
20 challenged 
(+ 15 for sampling) 
ORAL+DIP 3 x (7 d treated feed / 7 d untreated feed) 
+ Booster Immersion (Mean Wt. 1.78 g) 
20 challenged 
(+ 15 for sampling) 
1DIP Immersion (prior to exogenous feeding) 
20 challenged 
(+ 15 for sampling) 
2DIP 
Immersion (prior to exogenous feeding, Mean Wt. 0.26 
g) 
+ Booster Immersion (Mean Wt. 1.2 g) 
20 challenged 
(+ 15 for sampling) 
CONTROL No treatment 
20 challenged 
(+ 15 for sampling) 
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 Table 2: Primers and probes used for molecular analysis 
Immune gene expression analysis 
RAG-1 
Forward CCT AAC ACC TCT AGG CTT GAC 
Reverse GCT TCC CTG TTT ACT CGC 
IgMMB 
Forward TCT GGG TTG CAT TGC CAC TG 
Reverse GTA GCT TCC ACT GGT TTG GAC  
TCR-α 
Forward GCC TGG CTA CAG ATT TCA GC 
Reverse GGC AAC CTG GCT GTA GTA AGC 
Y. ruckeri detection/quantification 
Forward primer [11] AAC CCA GAT GGG ATT AGC TAG TAA 
Reverse primer [11] GTT CAG TGC TAT TAA CAC TTA ACC C 
Probe (Taqman) AGCCACACTGGAACTGAGACACGGTCC 
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Table 3: Percentage of challenge survivors identified as asymptomatic carriers in each 
group, and mean splenic bacterial load (expressed as number of Y. ruckeri 16S riboso-
mal gene copies detected) 
Group 
Asymptomatic carriers 
(%) 
Median Load 
(ribosomal 16S gene copies) 
ORAL 55.56 3.0 x 10
1
 
ORAL+DIP 51.43 1.30 x 10
2
 
1DIP 81.82 3.15 x 10
4
 
2DIP 66.67 8.72 x 10
4
 
CONTROL 59.09 3.23 x 10
1
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Figure 1: Fluorescent optical micrographs of samples from negative controls (A: Spleen, B: Kidney, C: 
Liver), and from fish fed vaccine-feed labelled with FITC (D: Spleen, E: Kidney, F: Liver). Bar=100µm 
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Figure 2: Survival post-challenge with Y. ruckeri in Atlantic salmon immunised orally or by immersion, 
with and without a booster immersion-immunisation at 1.0 g size. Different lowercase letters indicate 
significantly different treatments. 
 
